Michael R. Hayden - Publications

Affiliations: 
University of British Columbia, Vancouver, Vancouver, BC, Canada 
Area:
Biostatistics Biology

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Lemarié FL, Caron NS, Sanders SS, Schmidt ME, Nguyen YTN, Ko S, Xu X, Pouladi MA, Martin DDO, Hayden MR. Rescue of aberrant huntingtin palmitoylation ameliorates mutant huntingtin-induced toxicity. Neurobiology of Disease. 105479. PMID 34390831 DOI: 10.1016/j.nbd.2021.105479  1
2021 Caron NS, Anderson C, Black HF, Sanders SS, Lemarié FL, Doty CN, Hayden MR. Reliable Resolution of Full-Length Huntingtin Alleles by Quantitative Immunoblotting. Journal of Huntington's Disease. PMID 34092649 DOI: 10.3233/JHD-200463  1
2021 Zhemkov V, Geva M, Hayden MR, Bezprozvanny I. Sigma-1 Receptor (S1R) Interaction with Cholesterol: Mechanisms of S1R Activation and Its Role in Neurodegenerative Diseases. International Journal of Molecular Sciences. 22. PMID 33920913 DOI: 10.3390/ijms22084082  1
2021 Shenkman M, Geva M, Gershoni-Emek N, Hayden MR, Lederkremer GZ. Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the Sigma-1 receptor. Journal of Neurochemistry. PMID 33871049 DOI: 10.1111/jnc.15366  1
2021 Naia L, Ly P, Mota SI, Lopes C, Maranga C, Coelho P, Gershoni-Emek N, Ankarcrona M, Geva M, Hayden MR, Rego AC. The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33797036 DOI: 10.1007/s13311-021-01022-9  1
2021 Ravalia AS, Lau J, Barron J, Purchase S, Southwell AL, Hayden MR, Nafar F, Parsons MP. Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice. Neurobiology of Disease. 105293. PMID 33556538 DOI: 10.1016/j.nbd.2021.105293  1
2020 Caron NS, Banos R, Yanick C, Aly AE, Byrne LM, Smith ED, Xie Y, Smith SEP, Potluri N, Findlay Black H, Casal L, Ko S, Cheung D, Kim H, Seong IS, ... ... Hayden MR, et al. Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33310753 DOI: 10.1523/JNEUROSCI.1865-20.2020  1
2020 Schmidt ME, Caron NS, Aly AE, Lemarié FL, Dal Cengio L, Ko Y, Lazic N, Anderson L, Nguyen B, Raymond LA, Hayden MR. DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience. 14: 590569. PMID 33250715 DOI: 10.3389/fncel.2020.590569  1
2020 Niu J, Sanders SS, Jeong HK, Holland SM, Sun Y, Collura KM, Hernandez LM, Huang H, Hayden MR, Smith GM, Hu Y, Jin Y, Thomas GM. Coupled Control of Distal Axon Integrity and Somal Responses to Axonal Damage by the Palmitoyl Acyltransferase ZDHHC17. Cell Reports. 33: 108365. PMID 33207199 DOI: 10.1016/j.celrep.2020.108365  1
2020 Machiela E, Jeloka R, Caron NS, Mehta S, Schmidt ME, Baddeley HJE, Tom CM, Polturi N, Xie Y, Mattis VB, Hayden MR, Southwell AL. The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons. Frontiers in Aging Neuroscience. 12: 524369. PMID 33192449 DOI: 10.3389/Fnagi.2020.524369  1
2020 Wright GEB, Black HF, Collins JA, Gall-Duncan T, Caron NS, Pearson CE, Hayden MR. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies. The Lancet. Neurology. 19: 930-939. PMID 33098802 DOI: 10.1016/S1474-4422(20)30343-4  1
2020 Grachev ID, Meyer PM, Becker GA, Bronzel M, Marsteller D, Pastino G, Voges O, Rabinovich L, Knebel H, Zientek F, Rullmann M, Sattler B, Patt M, Gerhards T, Strauss M, ... ... Hayden MR, et al. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [F] fluspidine and [F] fallypride PET study. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32995944 DOI: 10.1007/s00259-020-05030-3  1
2020 Xu X, Ng B, Sim B, Radulescu CI, Yusof NABM, Goh WI, Lin S, Lim JSY, Cha Y, Kusko R, Kay C, Ratovitski T, Ross C, Hayden MR, Wright G, et al. pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model. Cell Death & Disease. 11: 809. PMID 32978366 DOI: 10.1038/s41419-020-02983-z  1
2020 Wright GEB, Caron NS, Ng B, Casal L, Casazza W, Xu X, Ooi J, Pouladi MA, Mostafavi S, Ross CJD, Hayden MR. Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease. Human Molecular Genetics. PMID 32898862 DOI: 10.1093/Hmg/Ddaa184  1
2020 Findlay Black H, Wright GEB, Collins JA, Caron N, Kay C, Xia Q, Arning L, Bijlsma EK, Squitieri F, Nguyen HP, Hayden MR. Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32741964 DOI: 10.1038/S41436-020-0917-Z  1
2020 Squitieri F, Mazza T, Maffi S, De Luca A, AlSalmi Q, AlHarasi S, Collins JA, Kay C, Baine-Savanhu F, Landwhermeyer BG, Sabatini U, Hayden MR. Tracing the mutated HTT and haplotype of the African ancestor who spread Huntington disease into the Middle East. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32661355 DOI: 10.1038/S41436-020-0895-1  1
2020 Skotte NH, Pouladi MA, Ehrnhoefer DE, Huynh K, Qiu X, Nielsen SMB, Nielsen TT, Nørremølle A, Hayden MR. Compromised IGF signaling causes caspase-6 activation in Huntington disease. Experimental Neurology. 113396. PMID 32622701 DOI: 10.1016/J.Expneurol.2020.113396  1
2020 Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD): optimizing its use in a clinical diagnostic or research setting. Human Genetics. PMID 32596782 DOI: 10.1007/s00439-020-02199-3  0.01
2020 McGarry A, Auinger P, Kieburtz K, Geva M, Mehra M, Abler V, Grachev ID, Gordon MF, Savola JM, Gandhi S, Papapetropoulos S, Hayden M. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease. Journal of Huntington's Disease. 9: 173-184. PMID 32508327 DOI: 10.3233/Jhd-190393  1
2020 Bartl S, Oueslati A, Southwell AL, Siddu A, Parth M, David LS, Maxan A, Salhat N, Burkert M, Mairhofer A, Pankevych H, Balazs K, Staffler G, Hayden MR, Cicchetti F, et al. Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. Neurobiology of Disease. 104943. PMID 32407769 DOI: 10.1016/J.Nbd.2020.104943  1
2019 Gordon MF, Grachev ID, Mazeh I, Dolan Y, Reilmann R, Loupe PS, Fine S, Navon-Perry L, Gross N, Papapetropoulos S, Savola JM, Hayden MR. Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices. Digital Biomarkers. 3: 103-115. PMID 32095771 DOI: 10.1159/000502136  1
2019 Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, Anderson LM, Ko S, Zhu X, van Deventer SJ, Evers MM, Konstantinova P, Hayden MR. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Research. PMID 31745548 DOI: 10.1093/Nar/Gkz976  1
2019 Kay C, Collins JA, Caron NS, Agostinho LA, Findlay-Black H, Casal L, Sumathipala D, Dissanayake VHW, Cornejo-Olivas M, Baine F, Krause A, Greenberg JL, Paiva CLA, Squitieri F, Hayden MR. A Comprehensive Haplotype Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. American Journal of Human Genetics. PMID 31708117 DOI: 10.1016/J.Ajhg.2019.10.011  1
2019 Winther M, Shpitzen S, Yaacov O, Landau J, Oren L, Foroozan-Rosenberg L, Lev Cohain N, Schurr D, Meiner V, Szalat A, Carmi S, Hayden MR, Leitersdorf E, Durst R. In search for genetic explanation for LDLc variabily in an FH family: Common SNPs and a rare mutation in microsomal triglyceride transfer protein explain only part of LDL variability in an FH family. Journal of Lipid Research. PMID 31387896 DOI: 10.1194/Jlr.M092049  0.01
2019 Ehrnhoefer DE, Skotte NH, Reinshagen J, Qiu X, Windshügel B, Jaishankar P, Ladha S, Petina O, Khankischpur M, Nguyen YTN, Caron NS, Razeto A, Meyer Zu Rheda M, Deng Y, Huynh KT, ... ... Hayden MR, et al. Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. Cell Chemical Biology. PMID 31353319 DOI: 10.1016/J.Chembiol.2019.07.001  1
2019 Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA. Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience. 13: 209. PMID 31156395 DOI: 10.3389/Fncel.2019.00209  1
2019 Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiology of Disease. PMID 31108174 DOI: 10.1016/J.Nbd.2019.05.009  1
2019 Wright GEB, Collins JA, Kay C, McDonald C, Dolzhenko E, Xia Q, Bečanović K, Drögemöller BI, Semaka A, Nguyen CM, Trost B, Richards F, Bijlsma EK, Squitieri F, Ross CJD, ... ... Hayden MR, et al. Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. American Journal of Human Genetics. PMID 31104771 DOI: 10.1016/J.Ajhg.2019.04.007  0.01
2019 Ferrari Bardile C, Garcia-Miralles M, Caron NS, Rayan NA, Langley SR, Harmston N, Rondelli AM, Teo RTY, Waltl S, Anderson LM, Bae HG, Jung S, Williams A, Prabhakar S, Petretto E, ... Hayden MR, et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 31015293 DOI: 10.1073/Pnas.1818042116  1
2019 Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Author Correction: Laquinimod treatment in the R6/2 mouse model. Scientific Reports. 9: 4960. PMID 30874566 DOI: 10.1038/S41598-018-37926-4  1
2019 Kang R, Wang L, Sanders SS, Zuo K, Hayden MR, Raymond LA. Altered Regulation of Striatal Neuronal -Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model. Frontiers in Synaptic Neuroscience. 11: 3. PMID 30846936 DOI: 10.3389/Fnsyn.2019.00003  1
2019 Ionescu A, Gradus T, Altman T, Maimon R, Saraf Avraham N, Geva M, Hayden M, Perlson E. Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1 Model. Cell Death & Disease. 10: 210. PMID 30824685 DOI: 10.1038/S41419-019-1451-2  1
2019 Francardo V, Geva M, Bez F, Denis Q, Steiner L, Hayden MR, Cenci MA. Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 30756361 DOI: 10.1007/S13311-018-00699-9  1
2019 Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB, et al. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. The Lancet. Neurology. 18: 165-176. PMID 30563778 DOI: 10.1016/S1474-4422(18)30391-0  1
2018 Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, Hayden M, Bezprozvanny I. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. Neurobiology of Disease. PMID 30594810 DOI: 10.1016/J.Nbd.2018.12.022  1
2018 Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30575996 DOI: 10.1002/Mds.27565  1
2018 Martin DDO, Schmidt ME, Nguyen YT, Lazic N, Hayden MR. Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201701510RRR. PMID 30423259 DOI: 10.1096/Fj.201701510Rrr  1
2018 Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. Molecular Neurobiology. PMID 30334188 DOI: 10.1007/S12035-018-1393-1  1
2018 Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, ... ... Hayden MR, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Science Translational Medicine. 10. PMID 30282695 DOI: 10.1126/Scitranslmed.Aar3959  1
2018 Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature Reviews. Drug Discovery. PMID 30237454 DOI: 10.1038/Nrd.2018.133  1
2018 Melamed-Gal S, Loupe P, Timan B, Weinstein V, Kolitz S, Zhang J, Funt J, Komlosh A, Ashkenazi N, Bar-Ilan O, Konya A, Beriozkin O, Laifenfeld D, Hasson T, Krispin R, ... ... Hayden MR, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. Eneurologicalsci. 12: 19-30. PMID 30094354 DOI: 10.1016/J.Ensci.2018.05.006  1
2018 Wright GEB, Amstutz U, Drögemöller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC, Ross CJD. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clinical Pharmacology and Therapeutics. PMID 29999516 DOI: 10.1002/Cpt.1179  1
2018 Schmidt ME, Buren C, Mackay JP, Cheung D, Dal Cengio L, Raymond LA, Hayden MR. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. Bmc Biology. 16: 58. PMID 29945611 DOI: 10.1186/S12915-018-0526-3  1
2018 Martin DDO, Kay C, Collins JA, Nguyen YT, Slama RA, Hayden MR. A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease. Scientific Reports. 8: 8096. PMID 29802276 DOI: 10.1038/S41598-018-25903-W  1
2018 Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Molecular Neurodegeneration. 13: 25. PMID 29783994 DOI: 10.1186/S13024-018-0259-3  1
2018 Petrella LI, Castelhano JM, Ribeiro M, Sereno JV, Gonçalves SI, Laço MN, Hayden MR, Rego AC, Castelo-Branco M. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. Human Molecular Genetics. PMID 29668904 DOI: 10.1093/Hmg/Ddy119  1
2018 Ladha S, Qiu X, Casal L, Caron NS, Ehrnhoefer DE, Hayden MR. Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli. Cell Death Discovery. 4: 40. PMID 29560279 DOI: 10.1038/S41420-018-0043-8  1
2018 Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR. Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathologica Communications. 6: 16. PMID 29510748 DOI: 10.1186/S40478-018-0518-0  1
2018 Chevre R, Trigueros-Motos L, Castaño D, Chua T, Corlianò M, Patankar JV, Sng L, Sim L, Juin TL, Carissimo G, Ng LFP, Yi CNJ, Eliathamby CC, Groen AK, Hayden MR, et al. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201701084RR. PMID 29481310 DOI: 10.1096/Fj.201701084Rr  1
2018 Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, ... ... Hayden MR, et al. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. PMID 29460498 DOI: 10.1002/Ajmg.B.32618  1
2018 Drögemöller BI, Brooks B, Monzon JG, Wright GE, Liu G, Renouf DJ, Kollmannsberger C, Bedard PL, Hayden MR, Gelmon KA, Carleton B, Ross CJ. Further investigation of the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29358504 DOI: 10.1158/1078-0432.Ccr-17-2810  1
2018 Bardile CF, Garcia-Miralles M, Caron N, Langley S, Teo RTY, Petretto E, Hayden MR, Pouladi MA. A43 Intrinsic mutant HTT-mediated defects in oligodendroglia cells contribute to myelin deficits and behavioural abnormalities in huntington disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.41  1
2018 Bartl S, Oueslati A, Southwell AL, Parth M, Salhat N, Siddu A, Burkert M, Pankevych H, David L, Villanueva EB, Xie Y, Cengio LD, Ko S, Hayden MR, Cicchetti F, et al. I09 Antibodies inhibit cell to cell transmission of mutant HTT Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.245  1
2018 Klein P, Karneva Z, Toonen L, Kim H, Caron N, Graaf Lvd, Buil L, Horst Gvd, Anthonijsz H, Ham Fvd, Beumer W, Hayden M, Song J, Roon-Mom Wv, Platenburg G. I01 QRX-704, a novel antisense oligonucleotide therapy, designed to prevent hd pathology while maintaining htt function Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.237  1
2017 Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. Jci Insight. 2. PMID 29212949 DOI: 10.1172/Jci.Insight.95665  1
2017 Grossman I, Kolitz S, Komlosh A, Zeskind B, Weinstein V, Laifenfeld D, Gilbert A, Bar-Ilan O, Fowler KD, Hasson T, Konya A, Wells-Knecht K, Loupe P, Melamed-Gal S, Molotsky T, ... ... Hayden MR, et al. Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model. Annals of the New York Academy of Sciences. 1407: 75-89. PMID 29168242 DOI: 10.1111/Nyas.13547  1
2017 Ehrnhoefer DE, Southwell AL, Sivasubramanian M, Qiu X, Villanueva EB, Xie Y, Waltl S, Anderson L, Fazeli A, Casal L, Felczak B, Tsang M, Hayden MR. HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. Human Molecular Genetics. PMID 29121340 DOI: 10.1093/Hmg/Ddx394  1
2017 Patankar JV, Wong CK, Morampudi V, Gibson WT, Vallance B, Ioannou GN, Hayden M. Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. American Journal of Physiology. Endocrinology and Metabolism. ajpendo.00172.2017. PMID 29066462 DOI: 10.1152/Ajpendo.00172.2017  1
2017 Kay C, Hayden MR, Leavitt BR. Epidemiology of Huntington disease. Handbook of Clinical Neurology. 144: 31-46. PMID 28947124 DOI: 10.1016/B978-0-12-801893-4.00003-1  1
2017 Silva AC, Ferreira IL, Hayden MR, Ferreiro E, Cristina Rego A. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease. Biochimica Et Biophysica Acta. PMID 28939435 DOI: 10.1016/J.Bbadis.2017.09.009  0.01
2017 Trigueros-Motos L, van Capelleveen JC, Torta F, Castaño D, Zhang LH, Chai C, Kang M, Dimova LG, Schimmel AWM, Tietjen I, Radomski C, Tan LJ, Hwee TC, Narayanaswamy P, Wu D, ... ... Hayden MR, et al. ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 28882873 DOI: 10.1161/Atvbaha.117.309574  1
2017 McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease. Journal of Huntington's Disease. PMID 28826192 DOI: 10.3233/Jhd-170241  1
2017 Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Laquinimod treatment in the R6/2 mouse model. Scientific Reports. 7: 4947. PMID 28694434 DOI: 10.1038/S41598-017-04990-1  1
2017 Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, Weiner B, Kusko R, Zeskind B, Knappertz V, Grossman I, Hayden MR. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Medicine. 9: 50. PMID 28569182 DOI: 10.1186/S13073-017-0436-Y  1
2017 Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, ... ... Hayden MR, et al. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. Jama Oncology. PMID 28448657 DOI: 10.1001/Jamaoncol.2017.0502  1
2017 Martin DDO, Hayden MR. Neurodegeneration: Role of repeats in protein clearance. Nature. PMID 28445458 DOI: 10.1038/Nature22489  1
2017 Aminkeng F, Ross CJ, Rassekh SR, Rieder MJ, Bhavsar AP, Sanatani S, Bernstein D, Hayden MR, Amstutz U, Carleton BC. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. British Journal of Clinical Pharmacology. PMID 28317142 DOI: 10.1111/Bcp.13218  1
2017 Mouton CP, Hayden M, Southerland JH. Cardiovascular Health Disparities in Underserved Populations. Primary Care. 44: e37-e71. PMID 28164826 DOI: 10.1016/J.Cpha.2018.08.010  0.01
2017 Naia L, Cunha-Oliveira T, Rodrigues J, Rosenstock TR, Oliveira A, Ribeiro M, Carmo C, Oliveira-Sousa SI, Duarte AI, Hayden MR, Rego AC. Histone deacetylase inhibitors protect against pyruvate dehydrogenase dysfunction in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28123081 DOI: 10.1523/Jneurosci.2006-14.2016  1
2017 Southwell AL, Skotte NH, Villanueva EB, Østergaard ME, Gu X, Kordasiewicz HB, Kay C, Cheung D, Xie Y, Waltl S, Dal Cengio L, Findlay-Black H, Doty CN, Petoukhov E, Iworima D, ... ... Hayden MR, et al. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics. PMID 28104789 DOI: 10.1093/Hmg/Ddx021  1
2017 Hayden MR, Kay C. Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 88: 334-335. PMID 28093515 DOI: 10.1212/Wnl.0000000000003528  1
2016 Kay C, Tirado-Hurtado I, Cornejo-Olivas M, Collins JA, Wright G, Inca-Martinez M, Veliz-Otani D, Ketelaar ME, Slama RA, Ross CJ, Mazzetti P, Hayden MR. The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. European Journal of Human Genetics : Ejhg. PMID 28000697 DOI: 10.1038/Ejhg.2016.169  1
2016 Sanders SS, Parsons MP, Mui KK, Southwell AL, Franciosi S, Cheung D, Waltl S, Raymond LA, Hayden MR. Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. Bmc Biology. 14: 108. PMID 27927242 DOI: 10.1186/S12915-016-0333-7  1
2016 Skotte NH, Sanders SS, Singaraja RR, Ehrnhoefer DE, Vaid K, Qiu X, Kannan S, Verma C, Hayden MR. Palmitoylation of caspase-6 by HIP14 regulates its activation. Cell Death and Differentiation. PMID 27911442 DOI: 10.1038/Cdd.2016.139  1
2016 Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiology of Disease. PMID 27818324 DOI: 10.1016/J.Nbd.2016.10.006  1
2016 Wright GE, Carleton B, Hayden MR, Ross CJ. The global spectrum of protein-coding pharmacogenomic diversity. The Pharmacogenomics Journal. PMID 27779249 DOI: 10.1038/Tpj.2016.77  1
2016 Jan A, Jansonius B, Delaidelli A, Somasekharan SP, Bhanshali F, Vandal M, Negri GL, Moerman D, MacKenzie I, Calon F, Hayden MR, Taubert S, Sorensen PH. eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathologica. PMID 27752775 DOI: 10.1007/S00401-016-1634-1  1
2016 Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, ... ... Hayden MR, et al. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America. PMID 27671624 DOI: 10.1073/Pnas.1607843113  1
2016 Naia L, Rosenstock TR, Oliveira AM, Oliveira-Sousa SI, Caldeira GL, Carmo C, Laço MN, Hayden MR, Oliveira CR, Rego AC. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models. Molecular Neurobiology. PMID 27590140 DOI: 10.1007/S12035-016-0048-3  1
2016 Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Scientific Reports. 6: 31652. PMID 27528441 DOI: 10.1136/Jnnp-2016-314597.263  1
2016 Geva M, Kusko R, Soares H, Fowler K, Birnberg T, Barash S, Merenlender Wagner A, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, ... ... Hayden MR, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Human Molecular Genetics. PMID 27466197 DOI: 10.1093/Hmg/Ddw238  1
2016 Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, Xie Y, Anderson L, Felczak B, Waltl S, Ko S, Cheung D, Dal Cengio L, Slama R, Petoukhov E, ... ... Hayden MR, et al. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Human Molecular Genetics. PMID 27378694 DOI: 10.1093/Hmg/Ddw212  1
2016 Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, Davidson M, Slama RA, Hayden MR. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. PMID 27335115 DOI: 10.1212/Wnl.0000000000002858  1
2016 Ehrnhoefer DE, Caron NS, Deng Y, Qiu X, Tsang M, Hayden MR. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Experimental Neurology. PMID 27296315 DOI: 10.1016/J.Expneurol.2016.06.008  1
2016 Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC. Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity. British Journal of Clinical Pharmacology. PMID 27197003 DOI: 10.1111/Bcp.13008  1
2016 Masellis M, Collinson S, Freeman N, Tampakeras M, Levy J, Tchelet A, Eyal E, Berkovich E, Eliaz RE, Abler V, Grossman I, Fitzer-Attas C, Tiwari A, Hayden MR, Kennedy JL, et al. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. Brain : a Journal of Neurology. PMID 27190009 DOI: 10.1093/Brain/Aww109  1
2016 Maillet A, Tan K, Chai X, Sadananda SN, Mehta A, Ooi J, Hayden MR, Pouladi MA, Ghosh S, Shim W, Brunham LR. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Scientific Reports. 6: 25333. PMID 27142468 DOI: 10.1038/Srep25333  1
2016 Teo RT, Hong X, Yu-Taeger L, Huang Y, Tan LJ, Xie Y, To XV, Guo L, Rajendran R, Novati A, Calaminus C, Riess O, Hayden MR, Nguyen HP, Chuang KH, et al. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Human Molecular Genetics. PMID 27126634 DOI: 10.1093/Hmg/Ddw122  1
2016 Connolly C, Magnusson-Lind A, Lu G, Wagner PK, Southwell AL, Hayden MR, Björkqvist M, Leavitt BR. Enhanced Immune Response to MMP3 stimulation in Microglia Expressing Mutant Huntingtin. Neuroscience. PMID 27033979 DOI: 10.1016/J.Neuroscience.2016.03.031  1
2016 Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P. Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. Molecular Therapy. Nucleic Acids. 5: e297. PMID 27003755 DOI: 10.1038/Mtna.2016.7  1
2016 Wijesekara N, Kaur A, Westwell-Roper C, Nackiewicz D, Soukhatcheva G, Hayden MR, Verchere CB. ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice. Diabetologia. PMID 26970755 DOI: 10.1007/S00125-016-3907-6  1
2016 Grossman I, Knappertz V, Laifenfeld D, Ross C, Zeskind B, Kolitz S, Ladkani D, Hayardeny L, Loupe P, Laufer R, Hayden M. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. Progress in Neurobiology. PMID 26952809 DOI: 10.1016/J.Pneurobio.2016.02.001  1
2016 Riechers SP, Butland S, Deng Y, Skotte N, Ehrnhoefer DE, Russ J, Laine J, Laroche M, Pouladi MA, Wanker EE, Hayden MR, Graham RK. Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. Human Molecular Genetics. PMID 26908611 DOI: 10.1093/Hmg/Ddw036  1
2016 Naia L, Ribeiro M, Rodrigues J, Duarte AI, Lopes C, Rosenstock TR, Hayden MR, Rego AC. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides. PMID 26876526 DOI: 10.1016/J.Npep.2016.01.009  1
2016 Garcia-Miralles M, Ooi J, Bardile CF, Tan LJ, George M, Drum CL, Lin RY, Hayden MR, Pouladi MA. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Experimental Neurology. PMID 26825854 DOI: 10.1016/J.Expneurol.2016.01.019  1
2016 Dobson L, Träger U, Farmer R, Hayardeny L, Loupe P, Hayden MR, Tabrizi SJ. Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. Journal of Neurochemistry. PMID 26823290 DOI: 10.1111/Jnc.13553  1
2016 Hasson T, Kolitz S, Towfic F, Laifenfeld D, Bakshi S, Beriozkin O, Shacham-Abramson M, Timan B, Fowler KD, Birnberg T, Konya A, Komlosh A, Ladkani D, Hayden MR, Zeskind B, et al. Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Journal of Neuroimmunology. 290: 84-95. PMID 26711576 DOI: 10.1016/J.Jneuroim.2015.11.020  1
2016 Hayden MR. A true mentor and pioneer in medical genetics South African Medical Journal. 106: S7-S9. DOI: 10.7196/Samj.2016.V106I6.11022  1
2016 García Pérez AE, Prieto CA, Holtzman JA, Shetrone M, Mészáros S, Bizyaev D, Carrera R, Cunha K, García-Hernández DA, Johnson JA, Majewski SR, Nidever DL, Schiavon RP, Shane N, Smith VV, ... ... Hayden MR, et al. ASPCAP: The APOGEE STELLAR PARAMETER and CHEMICAL ABUNDANCES PIPELINE Astronomical Journal. 151. DOI: 10.3847/0004-6256/151/6/144  1
2016 Hasson T, Kolitz S, Towfic F, Laifenfeld D, Bakshi S, Beriozkin O, Shacham-Abramson M, Timan B, Fowler KD, Birnberg T, Konya A, Komlosh A, Ladkani D, Hayden MR, Zeskind B, et al. Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition Journal of Neuroimmunology. 290: 84-95. DOI: 10.1016/j.jneuroim.2015.11.020  1
2015 Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Huntington disease. Nature Reviews. Disease Primers. 1: 15005. PMID 27188817 DOI: 10.1038/nrdp.2015.5  1
2015 Chan SL, Samaranayake N, Ross CJ, Toh MT, Carleton B, Hayden MR, Teo YY, Dissanayake VH, Brunham LR. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenetics and Genomics. PMID 26444257 DOI: 10.1097/Fpc.0000000000000182  1
2015 Patankar JV, Brunham LR, Hayden MR. Comment on Rickels et al. Loss-of-Function Mutations in ABCA1 and Enhanced β-Cell Secretory Capacity in Young Adults. Diabetes 2015;64:193-199. Diabetes. 64: e25-6; discussion e2. PMID 26294435 DOI: 10.2337/Db15-0518  1
2015 Sanders SS, Martin DD, Butland SL, Lavallée-Adam M, Calzolari D, Kay C, Yates JR, Hayden MR. Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers. Plos Computational Biology. 11: e1004405. PMID 26275289 DOI: 10.1371/Journal.Pcbi.1004405  1
2015 Sadananda SN, Foo JN, Toh MT, Cermakova L, Trigueros-Motos L, Chan T, Liany H, Collins J, Germai S, Singaraja RR, Hayden MR, Francis GA, Frohlich J, Khor CC, Brunham LR. Targeted Next-Generation Sequencing to Diagnose Disorders of HDL Cholesterol. Journal of Lipid Research. PMID 26255038 DOI: 10.1194/Jlr.P058891  1
2015 Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, ... Hayden MR, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature Genetics. PMID 26237429 DOI: 10.1038/Ng.3374  1
2015 Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 16: 1065-76. PMID 26230641 DOI: 10.2217/Pgs.15.61  1
2015 Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26201449 DOI: 10.1038/Mt.2015.128  1
2015 Southwell AL, Smith SE, Davis TR, Caron NS, Villanueva EB, Xie Y, Collins JA, Li Ye M, Sturrock A, Leavitt BR, Schrum AG, Hayden MR. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific Reports. 5: 12166. PMID 26174131 DOI: 10.1038/Srep12166  1
2015 Hitchcock E, Patankar JV, Tyson C, Hrynchak M, Hayden MR, Gibson WT. A novel microdeletion affecting the CETP gene raises HDL-associated cholesterol levels. Clinical Genetics. PMID 26126777 DOI: 10.1111/Cge.12633  1
2015 Kolitz S, Hasson T, Towfic F, Funt JM, Bakshi S, Fowler KD, Laifenfeld D, Grinspan A, Artyomov MN, Birnberg T, Schwartz R, Komlosh A, Hayardeny L, Ladkani D, Hayden MR, et al. Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Scientific Reports. 5: 10191. PMID 25998228 DOI: 10.1038/Srep10191  1
2015 Jan A, Karasinska JM, Kang MH, de Haan W, Ruddle P, Kaur A, Connolly C, Leavitt BR, Sorensen PH, Hayden MR. Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression. Neuroscience Letters. 598: 66-72. PMID 25957561 DOI: 10.1016/J.Neulet.2015.05.007  1
2015 Bečanović K, Nørremølle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G, Manoharan S, Doty CN, Beck J, Lahiri N, Portales-Casamar E, Warby SC, Connolly C, ... ... Hayden MR, et al. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease. Nature Neuroscience. 18: 807-16. PMID 25938884 DOI: 10.1038/Nn.4014  1
2015 Stroedicke M, Bounab Y, Strempel N, Klockmeier K, Yigit S, Friedrich RP, Chaurasia G, Li S, Hesse F, Riechers SP, Russ J, Nicoletti C, Boeddrich A, Wiglenda T, Haenig C, ... ... Hayden MR, et al. Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Research. 25: 701-13. PMID 25908449 DOI: 10.1101/Gr.182444.114  1
2015 Martin DD, Hayden MR. Post-translational myristoylation at the cross roads of cell death, autophagy and neurodegeneration. Biochemical Society Transactions. 43: 229-34. PMID 25849922 DOI: 10.1042/Bst20140281  1
2015 Sanders SS, Hayden MR. Aberrant palmitoylation in Huntington disease. Biochemical Society Transactions. 43: 205-10. PMID 25849918 DOI: 10.1042/Bst20140242  1
2015 Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Human Molecular Genetics. 24: 3257-71. PMID 25740845 DOI: 10.1093/Hmg/Ddv080  1
2015 Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Dar Santos R, Coleman AJ, Carter K, Creighton S, Bechtel N, Bohlen S, Reilmann R, Johnson HJ, Hayden MR, Tabrizi SJ, et al. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 393-401. PMID 25690257 DOI: 10.1002/Mds.26118  1
2015 Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, ... ... Hayden MR, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 76: 46-56. PMID 25662335 DOI: 10.1016/J.Nbd.2015.01.002  1
2015 Østergaard ME, Thomas G, Koller E, Southwell AL, Hayden MR, Seth PP. Biophysical and biological characterization of hairpin and molecular beacon RNase H active antisense oligonucleotides. Acs Chemical Biology. 10: 1227-33. PMID 25654188 DOI: 10.1021/Cb500880F  1
2015 Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, Offen D. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Human Molecular Genetics. 24: 2604-14. PMID 25616965 DOI: 10.1093/Hmg/Ddv023  1
2015 Brunham LR, Hayden MR. Human genetics of HDL: Insight into particle metabolism and function. Progress in Lipid Research. 58: 14-25. PMID 25601427 DOI: 10.1016/J.Plipres.2015.01.001  1
2015 Wong BK, Ehrnhoefer DE, Graham RK, Martin DD, Ladha S, Uribe V, Stanek LM, Franciosi S, Qiu X, Deng Y, Kovalik V, Zhang W, Pouladi MA, Shihabuddin LS, Hayden MR. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiology of Disease. 76: 24-36. PMID 25583186 DOI: 10.1016/J.Nbd.2014.12.030  1
2015 Sanders SS, Hou J, Sutton LM, Garside VC, Mui KK, Singaraja RR, Hayden MR, Hoodless PA. Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. Developmental Biology. 397: 257-66. PMID 25478910 DOI: 10.1016/J.Ydbio.2014.11.018  1
2015 Semaka A, Kay C, Belfroid RD, Bijlsma EK, Losekoot M, van Langen IM, van Maarle MC, Oosterloo M, Hayden MR, van Belzen MJ. A new mutation for Huntington disease following maternal transmission of an intermediate allele. European Journal of Medical Genetics. 58: 28-30. PMID 25464109 DOI: 10.1016/J.Ejmg.2014.11.005  1
2015 Ooi J, Hayden MR, Pouladi MA. Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. Molecular Neurobiology. 52: 1850-61. PMID 25398695 DOI: 10.1007/S12035-014-8974-4  1
2015 Kaur A, Patankar JV, de Haan W, Ruddle P, Wijesekara N, Groen AK, Verchere CB, Singaraja RR, Hayden MR. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes. 64: 1168-79. PMID 25338812 DOI: 10.2337/Db14-0716  1
2015 Brunham LR, Kang MH, Van Karnebeek C, Sadananda SN, Collins JA, Zhang LH, Sayson B, Miao F, Stockler S, Frohlich J, Cassiman D, Rabkin SW, Hayden MR. Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease. Jimd Reports. 18: 51-62. PMID 25308558 DOI: 10.1007/8904_2014_348  1
2015 Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR. Autophagy in Huntington disease and huntingtin in autophagy. Trends in Neurosciences. 38: 26-35. PMID 25282404 DOI: 10.1016/J.Tins.2014.09.003  1
2015 Sanders SS, Martin DDO, Butland SL, Lavallée-Adam M, Calzolari D, Kay C, Yates JR, Hayden MR. Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers Plos Computational Biology. 11. DOI: 10.1371/journal.pcbi.1004405  1
2015 Hayden M, Bolger D, Rand DH, Ricciardone F. Managing, Ending and Avoiding Wars in the Middle East Middle East Policy. 22: 1-31. DOI: 10.1111/mepo.12109  1
2015 Becanovic K, Nørremølle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G, Manoharan S, Doty CN, Beck J, Lahiri N, Portales-Casamar E, Warby SC, Connolly C, ... ... Hayden MR, et al. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease Nature Neuroscience. 18: 807-816. DOI: 10.1038/nn.4014  1
2015 Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry Molecular Therapy. DOI: 10.1038/mt.2015.128  1
2015 Jan A, Karasinska JM, Kang MH, Haan Wd, Ruddle P, Kaur A, Connolly C, Leavitt BR, Sorensen PH, Hayden MR. Corrigendum to "Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression'' [Neuroscience Letters 598 (2015) 66-72] Neuroscience Letters. 602: 172. DOI: 10.1016/J.Neulet.2015.06.047  1
2014 Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, ... Hayden MR, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. Plos One. 9: e107434. PMID 25207939 DOI: 10.1371/Journal.Pone.0107434  1
2014 Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR. Genetic markers of cisplatin-induced hearing loss in children. Clinical Pharmacology and Therapeutics. 96: 296-8. PMID 25141953 DOI: 10.1038/Clpt.2014.92  1
2014 Brown AM, Renaud Y, Ross C, Hansen M, Mongrain I, Valois D, Carleton BC, Hayden MR, Dubé MP, Tardif JC, Phillips MS. Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 15: 1185-95. PMID 25141894 DOI: 10.2217/Pgs.14.81  1
2014 Southwell AL, Skotte NH, Kordasiewicz HB, Østergaard ME, Watt AT, Carroll JB, Doty CN, Villanueva EB, Petoukhov E, Vaid K, Xie Y, Freier SM, Swayze EE, Seth PP, Bennett CF, ... Hayden MR, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2093-106. PMID 25101598 DOI: 10.1038/Mt.2014.153  1
2014 Kolitz SE, Towfic F, Grossman I, Hayden MR, Zeskind B. Use of genetic technologies to compare medicines. Clinical Genetics. 86: 441-446. PMID 25046029 DOI: 10.1111/Cge.12462  1
2014 de Haan W, Karasinska JM, Ruddle P, Hayden MR. Hepatic ABCA1 expression improves β-cell function and glucose tolerance. Diabetes. 63: 4076-82. PMID 25028523 DOI: 10.2337/Db14-0548  1
2014 Pitarokoili K, Ambrosius B, Schrewe L, Hayardeny L, Hayden M, Gold R. Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis. Journal of Neuroimmunology. 274: 38-45. PMID 25005118 DOI: 10.1016/J.Jneuroim.2014.06.012  1
2014 Rinninger F, Heine M, Singaraja R, Hayden M, Brundert M, Ramakrishnan R, Heeren J. High density lipoprotein metabolism in low density lipoprotein receptor-deficient mice. Journal of Lipid Research. 55: 1914-24. PMID 24954421 DOI: 10.1194/Jlr.M048819  1
2014 Singaraja RR, Tietjen I, Hovingh GK, Franchini PL, Radomski C, Wong K, vanHeek M, Stylianou IM, Lin L, Wang L, Mitnaul L, Hubbard B, Winther M, Mattice M, Legendre A, ... ... Hayden MR, et al. Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. Journal of Lipid Research. 55: 1693-1701. PMID 24891332 DOI: 10.1194/Jlr.M048710  1
2014 Brunham LR, Chan SL, Li R, Aminkeng F, Liu X, Saw WY, Ong RT, Pillai EN, Carleton BC, Toh D, Tan SH, Koo SH, Lee EJ, Chia KS, Ross CJ, ... Hayden MR, et al. Pharmacogenomic diversity in Singaporean populations and Europeans. The Pharmacogenomics Journal. 14: 555-63. PMID 24861855 DOI: 10.1038/Tpj.2014.22  1
2014 Zhang SC, Bruce C, Hayden M, Rieder MJ. Public perceptions of pharmacogenetics. Pediatrics. 133: e1258-67. PMID 24777223 DOI: 10.1542/Peds.2013-1416  1
2014 Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR. Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity". Clinical Pharmacology and Therapeutics. 96: 158. PMID 24755913 DOI: 10.1038/Clpt.2014.90  1
2014 Lam J, Woodall KL, Solbeck P, Ross CJ, Carleton BC, Hayden MR, Koren G, Madadi P. Codeine-related deaths: The role of pharmacogenetics and drug interactions. Forensic Science International. 239: 50-6. PMID 24747667 DOI: 10.1016/J.Forsciint.2014.03.018  1
2014 Kolodziejczyk K, Parsons MP, Southwell AL, Hayden MR, Raymond LA. Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease. Plos One. 9: e94562. PMID 24728353 DOI: 10.1371/Journal.Pone.0094562  1
2014 Butland SL, Sanders SS, Schmidt ME, Riechers SP, Lin DT, Martin DD, Vaid K, Graham RK, Singaraja RR, Wanker EE, Conibear E, Hayden MR. The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease. Human Molecular Genetics. 23: 4142-60. PMID 24705354 DOI: 10.1093/Hmg/Ddu137  1
2014 Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clinical Genetics. 86: 21-8. PMID 24684508 DOI: 10.1111/Cge.12392  1
2014 Sanders SS, Mui KK, Sutton LM, Hayden MR. Identification of binding sites in Huntingtin for the Huntingtin Interacting Proteins HIP14 and HIP14L. Plos One. 9: e90669. PMID 24651384 DOI: 10.1371/Journal.Pone.0090669  1
2014 Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clinical Genetics. 86: 29-36. PMID 24646433 DOI: 10.1111/Cge.12385  1
2014 Rotblat B, Southwell AL, Ehrnhoefer DE, Skotte NH, Metzler M, Franciosi S, Leprivier G, Somasekharan SP, Barokas A, Deng Y, Tang T, Mathers J, Cetinbas N, Daugaard M, Kwok B, ... ... Hayden MR, et al. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proceedings of the National Academy of Sciences of the United States of America. 111: 3032-7. PMID 24516159 DOI: 10.1073/Pnas.1314421111  1
2014 Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatric Blood & Cancer. 61: 1055-62. PMID 24474498 DOI: 10.1002/Pbc.24932  1
2014 Martin DD, Heit RJ, Yap MC, Davidson MW, Hayden MR, Berthiaume LG. Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. Human Molecular Genetics. 23: 3166-79. PMID 24459296 DOI: 10.1093/Hmg/Ddu027  1
2014 de Haan W, Bhattacharjee A, Ruddle P, Kang MH, Hayden MR. ABCA1 in adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity. Journal of Lipid Research. 55: 516-23. PMID 24443560 DOI: 10.1194/Jlr.M045294  1
2014 Towfic F, Funt JM, Fowler KD, Bakshi S, Blaugrund E, Artyomov MN, Hayden MR, Ladkani D, Schwartz R, Zeskind B. Comparing the biological impact of glatiramer acetate with the biological impact of a generic. Plos One. 9: e83757. PMID 24421904 DOI: 10.1371/Journal.Pone.0083757  1
2014 Lopes C, Ribeiro M, Duarte AI, Humbert S, Saudou F, Pereira de Almeida L, Hayden M, Rego AC. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. Molecular Neurobiology. 49: 1126-42. PMID 24347322 DOI: 10.1007/S12035-013-8585-5  1
2014 Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN, Sanders SS, Hayden MR, Raymond LA. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin. The Journal of Biological Chemistry. 289: 3518-28. PMID 24347167 DOI: 10.1074/Jbc.M113.513945  1
2014 Semaka A, Hayden MR. Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results Clinical Genetics. 85: 303-311. PMID 24256063 DOI: 10.1111/Cge.12324  1
2014 Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clinical Pharmacology and Therapeutics. 95: 253. PMID 24193170 DOI: 10.1038/Clpt.2013.219  1
2014 Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 105-14. PMID 24151181 DOI: 10.1002/Mds.25717  1
2014 Ehrnhoefer DE, Skotte NH, Ladha S, Nguyen YT, Qiu X, Deng Y, Huynh KT, Engemann S, Nielsen SM, Becanovic K, Leavitt BR, Hasholt L, Hayden MR. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Human Molecular Genetics. 23: 717-29. PMID 24070868 DOI: 10.1093/Hmg/Ddt458  1
2014 Bochem AE, van Capelleveen JC, Dallinga-Thie GM, Schimmel AW, Motazacker MM, Tietjen I, Singaraja RR, Hayden MR, Kastelein JJ, Stroes ES, Hovingh GK. Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families. Clinical Genetics. 85: 433-40. PMID 23701270 DOI: 10.1111/Cge.12201  1
2014 Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. The Pharmacogenomics Journal. 14: 160-70. PMID 23588107 DOI: 10.1038/Tpj.2013.13  1
2014 Sanders SS, Mui KKN, Sutton LM, Hayden MR. A schematic diagram of the two hypothetical binding scenarios of HTT with HIP14 or HIP14L. Plos One. DOI: 10.1371/Journal.Pone.0090669.G005  1
2014 Hayden MR. Developmental Biology: Frontiers for Clinical Genetics Clinical Genetics. 86. DOI: 10.1111/Cge.12429  0.01
2014 Carleton BC, Ross CJ, Hayden MR. Genetic markers of cisplatin-induced hearing loss in children Clinical Advances in Hematology and Oncology. 12: 527-528.  1
2013 Stanek LM, Yang W, Angus S, Sardi PS, Hayden MR, Hung GH, Bennett CF, Cheng SH, Shihabuddin LS. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. Journal of Huntington's Disease. 2: 217-28. PMID 25063516 DOI: 10.3233/Jhd-130057  1
2013 Milnerwood AJ, Parsons MP, Young FB, Singaraja RR, Franciosi S, Volta M, Bergeron S, Hayden MR, Raymond LA. Memory and synaptic deficits in Hip14/DHHC17 knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 110: 20296-301. PMID 24277827 DOI: 10.1073/Pnas.1222384110  1
2013 Wan J, Savas JN, Roth AF, Sanders SS, Singaraja RR, Hayden MR, Yates JR, Davis NG. Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease. Chemistry & Biology. 20: 1421-34. PMID 24211138 DOI: 10.1016/J.Chembiol.2013.09.018  1
2013 Franciosi S, Shim Y, Lau M, Hayden MR, Leavitt BR. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1987-94. PMID 24142393 DOI: 10.1002/Mds.25663  1
2013 Kang MH, Zhang LH, Wijesekara N, de Haan W, Butland S, Bhattacharjee A, Hayden MR. Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arteriosclerosis, Thrombosis, and Vascular Biology. 33: 2724-32. PMID 24135019 DOI: 10.1161/Atvbaha.113.302004  1
2013 Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nature Reviews. Neuroscience. 14: 708-21. PMID 24052178 DOI: 10.1038/Nrn3570  1
2013 Semaka A, Kay C, Doty CN, Collins JA, Tam N, Hayden MR. High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 162: 864-71. PMID 24038799 DOI: 10.1002/Ajmg.B.32193  1
2013 Østergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN, Vaid K, Villanueva EB, Swayze EE, Bennett CF, Hayden MR, Seth PP. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS Nucleic Acids Research. 41: 9634-9650. PMID 23963702 DOI: 10.1093/Nar/Gkt725  1
2013 Houge G, Bruland O, Bjørnevoll I, Hayden MR, Semaka A. De novo Huntington disease caused by 26-44 CAG repeat expansion on a low-risk haplotype. Neurology. 81: 1099-100. PMID 23946314 DOI: 10.1212/Wnl.0B013E3182A4A4Af  1
2013 Bhavsar AP, Brown NF, Stoepel J, Wiermer M, Martin DD, Hsu KJ, Imami K, Ross CJ, Hayden MR, Foster LJ, Li X, Hieter P, Finlay BB. The Salmonella type III effector SspH2 specifically exploits the NLR co-chaperone activity of SGT1 to subvert immunity. Plos Pathogens. 9: e1003518. PMID 23935490 DOI: 10.1371/Journal.Ppat.1003518  1
2013 Kelly LE, Chaudhry SA, Rieder MJ, 't Jong G, Moretti ME, Lausman A, Ross C, Berger H, Carleton B, Hayden MR, Madadi P, Koren G. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. Plos One. 8: e70073. PMID 23922910 DOI: 10.1371/Journal.Pone.0070073  1
2013 Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR. CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. Journal of Medical Genetics. 50: 696-703. PMID 23896435 DOI: 10.1136/Jmedgenet-2013-101796  1
2013 Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, et al. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nature Medicine. 19: 1030-8. PMID 23852340 DOI: 10.1038/Nm.3246  1
2013 Shaw K, Amstutz U, Castro-Pastrana L, Loo TT, Ross CJ, Ito S, Reider MJ, Maher M, Macleod S, Koren G, Hayden MR, Carleton BC. Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT. Journal of Population Therapeutics and Clinical Pharmacology = Journal De La ThéRapeutique Des Populations Et De La Pharamcologie Clinique. 20: e110-27. PMID 23824325  1
2013 West GF, Hayden MR, Benjamin CR. Accuracy of adults' perception of childhood obesity in a military environment. Public Health Nursing (Boston, Mass.). 30: 343-50. PMID 23808859 DOI: 10.1111/phn.12001  1
2013 Lam J, Kelly L, Matok I, Ross CJ, Carleton BC, Hayden MR, Madadi P, Koren G. Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. Therapeutic Drug Monitoring. 35: 466-72. PMID 23783165 DOI: 10.1097/Ftd.0B013E318288F158  1
2013 Madadi P, Sistonen J, Silverman G, Gladdy R, Ross CJ, Carleton BC, Carvalho JC, Hayden MR, Koren G. Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful? Pain Research & Management : the Journal of the Canadian Pain Society = Journal De La SociéTé Canadienne Pour Le Traitement De La Douleur. 18: 133-6. PMID 23748253 DOI: 10.1155/2013/518012  1
2013 Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, et al. Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics. 14: 173-9. PMID 23644918 DOI: 10.1007/S10048-013-0364-Y  1
2013 Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clinical Pharmacology and Therapeutics. 94: 142-9. PMID 23588310 DOI: 10.1038/Clpt.2013.55  1
2013 Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Zada YF, Dubé MP, Carleton BC, Hayden MR. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clinical Pharmacology and Therapeutics. 94: 243-51. PMID 23588304 DOI: 10.1038/Clpt.2013.80  1
2013 Kastelein JJ, Ross CJ, Hayden MR. From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. Human Gene Therapy. 24: 472-8. PMID 23578007 DOI: 10.1089/Hum.2013.063  1
2013 Rassekh SR, Ross CJ, Carleton BC, Hayden MR. Cancer pharmacogenomics in children: research initiatives and progress to date. Paediatric Drugs. 15: 71-81. PMID 23529868 DOI: 10.1007/S40272-013-0021-9  1
2013 Brunham LR, Hayden MR. Hunting human disease genes: lessons from the past, challenges for the future. Human Genetics. 132: 603-17. PMID 23504071 DOI: 10.1007/S00439-013-1286-3  1
2013 Baine FK, Kay C, Ketelaar ME, Collins JA, Semaka A, Doty CN, Krause A, Greenberg LJ, Hayden MR. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. European Journal of Human Genetics : Ejhg. 21: 1120-7. PMID 23463025 DOI: 10.1038/Ejhg.2013.2  1
2013 Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatric Blood & Cancer. 60: 1375-81. PMID 23441093 DOI: 10.1002/Pbc.24505  1
2013 Karasinska JM, de Haan W, Franciosi S, Ruddle P, Fan J, Kruit JK, Stukas S, Lütjohann D, Gutmann DH, Wellington CL, Hayden MR. ABCA1 influences neuroinflammation and neuronal death. Neurobiology of Disease. 54: 445-55. PMID 23376685 DOI: 10.1016/J.Nbd.2013.01.018  1
2013 Singaraja RR, Sivapalaratnam S, Hovingh K, Dubé MP, Castro-Perez J, Collins HL, Adelman SJ, Riwanto M, Manz J, Hubbard B, Tietjen I, Wong K, Mitnaul LJ, van Heek M, Lin L, ... ... Hayden MR, et al. The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. Circulation. Cardiovascular Genetics. 6: 54-62. PMID 23243195 DOI: 10.1161/Circgenetics.111.962613  1
2013 Virani AKH, Creighton SM, Hayden MR. Developing a comprehensive, effective patient-friendly website to enhance decision making in predictive testing for Huntington disease Genetics in Medicine. 15: 466-472. PMID 23222664 DOI: 10.1038/Gim.2012.149  1
2013 Sutton LM, Sanders SS, Butland SL, Singaraja RR, Franciosi S, Southwell AL, Doty CN, Schmidt ME, Mui KK, Kovalik V, Young FB, Zhang W, Hayden MR. Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. Human Molecular Genetics. 22: 452-65. PMID 23077216 DOI: 10.1093/Hmg/Dds441  1
2013 Hawkins A, Creighton S, Ho A, Mcmanus B, Hayden M. Providing predictive testing for Huntington disease via telehealth: Results of a pilot study in British Columbia, Canada Clinical Genetics. 84: 60-64. PMID 23039041 DOI: 10.1111/cge.12033  1
2013 Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, Villanueva EB, Kovalik V, Xie Y, Pouladi MA, Collins JA, Yang XW, Franciosi S, Hayden MR. A fully humanized transgenic mouse model of Huntington disease. Human Molecular Genetics. 22: 18-34. PMID 23001568 DOI: 10.1093/Hmg/Dds397  1
2013 Semaka A, Balneaves LG, Hayden MR. "Grasping the grey": Patient understanding and interpretation of an intermediate allele predictive test result for huntington disease Journal of Genetic Counseling. 22: 200-217. PMID 22903792 DOI: 10.1007/S10897-012-9533-7  1
2013 Van Raam BJ, Ehrnhoefer DE, Hayden MR, Salvesen GS. Intrinsic cleavage of receptor-interacting protein kinase-1 by caspase-6 Cell Death and Differentiation. 20: 86-96. PMID 22858542 DOI: 10.1038/Cdd.2012.98  1
2013 Hawkins AK, Creighton S, Hayden MR. When access is an issue: exploring barriers to predictive testing for Huntington disease in British Columbia, Canada. European Journal of Human Genetics : Ejhg. 21: 148-53. PMID 22781094 DOI: 10.1038/Ejhg.2012.147  1
2013 Hayden MR. Special new feature in Clinical Genetics Clinical Genetics. 83: 1. DOI: 10.1111/Cge.12067  1
2013 Qureshi A, Karasinska J, Kang M, Kaur A, Ruddle P, Franciosi S, Hayden M. Antisense oligonucleotide-mediated inhibition of miR-33 in cultured neurons, astrocytes and microglia: Effects on ABCA1 expression, APOE lipidation, cellular cholesterol and beta-amyloid neurotoxicity Alzheimers & Dementia. 9: 893. DOI: 10.1016/J.Jalz.2013.08.263  1
2012 Graham RK, Deng Y, Pouladi MA, Vaid K, Ehrnhoefer D, Southwell AL, Bissada N, Franciosi S, Hayden MR. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. Journal of Huntington's Disease. 1: 243-60. PMID 25063333 DOI: 10.3233/Jhd-120038  1
2012 Strong MK, Southwell AL, Yonan JM, Hayden MR, Macgregor GR, Thompson LM, Steward O. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. Journal of Huntington's Disease. 1: 221-41. PMID 23833693 DOI: 10.3233/Jhd-129005  1
2012 Southwell AL, Skotte NH, Bennett CF, Hayden MR. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine. 18: 634-43. PMID 23026741 DOI: 10.1016/J.Molmed.2012.09.001  1
2012 Khetani JD, Madadi P, Sommer DD, Reddy D, Sistonen J, Ross CJ, Carleton BC, Hayden MR, Koren G. Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study. Paediatric Drugs. 14: 411-5. PMID 23013460 DOI: 10.2165/11633570-000000000-00000  1
2012 Tietjen I, Hovingh GK, Singaraja RR, Radomski C, Barhdadi A, McEwen J, Chan E, Mattice M, Legendre A, Franchini PL, Dubé MP, Kastelein JJ, Hayden MR. Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol. Plos One. 7: e37437. PMID 22952570 DOI: 10.1371/Journal.Pone.0037437  1
2012 Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, et al. Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Human Genetics. 131: 1833-40. PMID 22825315 DOI: 10.1007/S00439-012-1205-Z  1
2012 Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Néri C, Hayden MR. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 48: 282-9. PMID 22796360 DOI: 10.1016/J.Nbd.2012.06.026  1
2012 Lam J, Matlow JN, Ross CJ, Hayden MR, Carleton BC, Madadi P. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: the devil is in the details. Therapeutic Drug Monitoring. 34: 378-80. PMID 22777151 DOI: 10.1097/Ftd.0B013E31825Da19F  1
2012 Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, et al. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochemical and Biophysical Research Communications. 424: 404-8. PMID 22771793 DOI: 10.1016/J.Bbrc.2012.06.120  1
2012 Brunham LR, Hayden MR. Medicine. Whole-genome sequencing: the new standard of care? Science (New York, N.Y.). 336: 1112-3. PMID 22654044 DOI: 10.1126/Science.1220967  1
2012 Pouladi MA, Hayden MR. Polyglutamine diseases and the risk of cancer. The Lancet. Oncology. 13: 569-71. PMID 22652230 DOI: 10.1016/S1470-2045(12)70167-5  1
2012 Young FB, Franciosi S, Spreeuw A, Deng Y, Sanders S, Tam NC, Huang K, Singaraja RR, Zhang W, Bissada N, Kay C, Hayden MR. Low levels of human HIP14 are sufficient to rescue neuropathological, behavioural, and enzymatic defects due to loss of murine HIP14 in Hip14-/- mice. Plos One. 7: e36315. PMID 22649491 DOI: 10.1371/Journal.Pone.0036315  1
2012 Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 129: e1343-7. PMID 22492761 DOI: 10.1542/Peds.2011-2538  1
2012 Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer ML, Nauta M, Carleton BC, Koren G, Hayden MR. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clinical Pharmacology and Therapeutics. 91: 692-9. PMID 22398969 DOI: 10.1038/Clpt.2011.280  1
2012 Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Griguoli A, Di Donato S, Gomez-Tortosa E, Ayuso C, et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. American Journal of Human Genetics. 90: 434-44. PMID 22387017 DOI: 10.1016/J.Ajhg.2012.01.005  1
2012 Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Human Molecular Genetics. 21: 2219-32. PMID 22328089 DOI: 10.1093/Hmg/Dds037  1
2012 Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 78: 690-5. PMID 22323755 DOI: 10.1212/Wnl.0B013E318249F683  1
2012 Wijesekara N, Zhang LH, Kang MH, Abraham T, Bhattacharjee A, Warnock GL, Verchere CB, Hayden MR. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes. 61: 653-8. PMID 22315319 DOI: 10.2337/Db11-0944  1
2012 Kruit JK, Wijesekara N, Westwell-Roper C, Vanmierlo T, de Haan W, Bhattacharjee A, Tang R, Wellington CL, LütJohann D, Johnson JD, Brunham LR, Verchere CB, Hayden MR. Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired β-cell function. Diabetes. 61: 659-64. PMID 22315310 DOI: 10.2337/Db11-1341  1
2012 Uribe V, Wong BK, Graham RK, Cusack CL, Skotte NH, Pouladi MA, Xie Y, Feinberg K, Ou Y, Ouyang Y, Deng Y, Franciosi S, Bissada N, Spreeuw A, Zhang W, ... ... Hayden MR, et al. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Human Molecular Genetics. 21: 1954-67. PMID 22262731 DOI: 10.1093/Hmg/Dds005  1
2012 Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Bottorff JL, Hayden MR. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 159: 217-26. PMID 22231990 DOI: 10.1002/Ajmg.B.32016  1
2012 Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, Graham RK, Hayden MR, Hou Z, Mori S, Swing D, Pletnikov M, Duan W, Tessarollo L, Ross CA. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 183-93. PMID 22219281 DOI: 10.1523/Jneurosci.1305-11.2012  1
2012 Young FB, Butland SL, Sanders SS, Sutton LM, Hayden MR. Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases. Progress in Neurobiology. 97: 220-38. PMID 22155432 DOI: 10.1016/J.Pneurobio.2011.11.002  1
2012 Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C, Price J, Young CE, Verschoof H, Sherrington R, Pimstone SN, Hayden MR. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 153: 80-5. PMID 22035805 DOI: 10.1016/J.Pain.2011.09.008  1
2012 Ketelaar ME, Hofstra RMW, Hayden MR. What monozygotic twins discordant for phenotype illustrate about mechanisms influencing genetic forms of neurodegeneration Clinical Genetics. 81: 325-333. PMID 21981075 DOI: 10.1111/j.1399-0004.2011.01795.x  1
2012 Franciosi S, Ryu JK, Shim Y, Hill A, Connolly C, Hayden MR, McLarnon JG, Leavitt BR. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 45: 438-49. PMID 21946335 DOI: 10.1016/J.Nbd.2011.09.003  1
2012 Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, ... ... Hayden MR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1422-8. PMID 21900104 DOI: 10.1200/Jco.2010.34.3467  1
2012 Lam J, Kelly L, Ciszkowski C, Landsmeer ML, Nauta M, Carleton BC, Hayden MR, Madadi P, Koren G. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. The Journal of Pediatrics. 160: 33-7.e2. PMID 21880331 DOI: 10.1016/J.Jpeds.2011.06.050  1
2012 Dionne F, Mitton C, Rassekh R, Brooks B, Ross C, Hayden M, Carleton B. Economic impact of a genetic test for cisplatin-induced ototoxicity. The Pharmacogenomics Journal. 12: 205-13. PMID 21502965 DOI: 10.1038/Tpj.2011.15  1
2012 Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. The Pharmacogenomics Journal. 12: 233-7. PMID 21243006 DOI: 10.1038/Tpj.2010.92  1
2012 Bombard Y, Semaka A, Hayden MR. Adoption and the communication of genetic risk: Experiences in Huntington disease Clinical Genetics. 81: 64-69. PMID 21204796 DOI: 10.1111/J.1399-0004.2010.01614.X  1
2012 Hawkins A, Creighton S, Hayden M. N02 Providing predictive testing via telehealth to improve access to predictive testing for HD: results of a pilot study Journal of Neurology, Neurosurgery, and Psychiatry. 83. DOI: 10.1136/Jnnp-2012-303524.153  1
2012 Brunham LR, Hayden MR. Response Science. 337: 911. DOI: 10.1126/Science.337.6097.911-A  1
2012 Dionne F, Mitton C, Rassekh R, Brooks B, Ross C, Hayden M, Carleton B. Erratum: Economic impact of a genetic test for cisplatin-induced ototoxicity Pharmacogenomics Journal. 12: 359-359. DOI: 10.1038/Tpj.2011.21  1
2012 Hayden MR, Salam M, Sowers JR. Reactive oxygen species and diabetic peripheral neuropathy - A closer look Systems Biology of Free Radicals and Antioxidants. 3375-3403. DOI: 10.1007/978-3-642-30018-9_157  1
2011 Ehrnhoefer DE, Skotte NH, Savill J, Nguyen YT, Ladha S, Cao LP, Dullaghan E, Hayden MR. A quantitative method for the specific assessment of caspase-6 activity in cell culture. Plos One. 6: e27680. PMID 22140457 DOI: 10.1371/Journal.Pone.0027680  1
2011 Graham RK, Ehrnhoefer DE, Hayden MR. Caspase-6 and neurodegeneration. Trends in Neurosciences. 34: 646-56. PMID 22018804 DOI: 10.1016/J.Tins.2011.09.001  1
2011 Ehrnhoefer DE, Wong BK, Hayden MR. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nature Reviews. Drug Discovery. 10: 853-67. PMID 22015920 DOI: 10.1038/Nrd3556  1
2011 Kruit JK, Wijesekara N, Fox JE, Dai XQ, Brunham LR, Searle GJ, Morgan GP, Costin AJ, Tang R, Bhattacharjee A, Johnson JD, Light PE, Marsh BJ, Macdonald PE, Verchere CB, ... Hayden MR, et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes. 60: 3186-96. PMID 21998401 DOI: 10.2337/Db11-0081  1
2011 Ding Y, Zhang L, Wang Y, Huang W, Tang Y, Bai L, Ross CJ, Hayden MR, Liu G. Amelioration of hypertriglyceridemia with hypo-alpha-cholesterolemia in LPL deficient mice by hematopoietic cell-derived LPL. Plos One. 6: e25620. PMID 21980507 DOI: 10.1371/Journal.Pone.0025620  1
2011 Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 2178-85. PMID 21971427 DOI: 10.1038/Mt.2011.201  1
2011 Hawkins AK, Ho A, Hayden MR. Lessons from predictive testing for Huntington disease: 25 years on Journal of Medical Genetics. 48: 649-650. PMID 21931167 DOI: 10.1136/Jmedgenet-2011-100352  1
2011 Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease Nature Reviews Neurology. 7: 561-572. PMID 21894212 DOI: 10.1038/Nrneurol.2011.132  1
2011 Carroll JB, Southwell AL, Graham RK, Lerch JP, Ehrnhoefer DE, Cao LP, Zhang WN, Deng Y, Bissada N, Henkelman RM, Hayden MR. Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Molecular Neurodegeneration. 6: 59. PMID 21854568 DOI: 10.1186/1750-1326-6-59  1
2011 Singaraja RR, Huang K, Sanders SS, Milnerwood AJ, Hines R, Lerch JP, Franciosi S, Drisdel RC, Vaid K, Young FB, Doty C, Wan J, Bissada N, Henkelman RM, Green WN, ... ... Hayden MR, et al. Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Human Molecular Genetics. 20: 3899-909. PMID 21775500 DOI: 10.1093/Hmg/Ddr308  1
2011 VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, Hayden MR, Koren G. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Therapeutic Drug Monitoring. 33: 425-32. PMID 21743374 DOI: 10.1097/Ftd.0B013E3182272B10  1
2011 Joly Y, Koutrikas G, Ramos-Paque E, Zawati M, Gardy J, Hayden MR, Carleton BC. Diagnostic testing for vaccinomics: is the regulatory approval framework adequate? A comparison of Canada, the United States, and Europe. Omics : a Journal of Integrative Biology. 15: 597-605. PMID 21728814 DOI: 10.1089/Omi.2010.0135  1
2011 Huang K, Sanders SS, Kang R, Carroll JB, Sutton L, Wan J, Singaraja R, Young FB, Liu L, El-Husseini A, Davis NG, Hayden MR. Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14. Human Molecular Genetics. 20: 3356-65. PMID 21636527 DOI: 10.1093/Hmg/Ddr242  1
2011 Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiology of Disease. 43: 257-65. PMID 21458571 DOI: 10.1016/J.Nbd.2011.03.018  1
2011 Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. Journal of Cardiovascular Pharmacology. 58: 228-39. PMID 21386709 DOI: 10.1097/Fjc.0B013E3182163B82  1
2011 Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, Bossy B, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nature Medicine. 17: 377-82. PMID 21336284 DOI: 10.1038/Nm.2313  1
2011 Ehrnhoefer DE, Sutton L, Hayden MR. Small changes, big impact: Posttranslational modifications and function of huntingtin in huntington disease Neuroscientist. 17: 475-492. PMID 21311053 DOI: 10.1177/1073858410390378  1
2011 Hawkins AK, Hayden MR. A grand challenge: Providing benefits of clinical genetics to those in need Genetics in Medicine. 13: 197-200. PMID 21283011 DOI: 10.1097/Gim.0B013E31820C056E  1
2011 Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, Hayden AR, Kanazawa I, Ross CJ, Hayden MR. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. European Journal of Human Genetics : Ejhg. 19: 561-6. PMID 21248742 DOI: 10.1038/Ejhg.2010.229  1
2011 Ye D, Zhao Y, Hildebrand RB, Singaraja RR, Hayden MR, Van Berkel TJ, Van Eck M. The dynamics of macrophage infiltration into the arterial wall during atherosclerotic lesion development in low-density lipoprotein receptor knockout mice. The American Journal of Pathology. 178: 413-22. PMID 21224078 DOI: 10.1016/J.Ajpath.2010.11.007  1
2011 Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Paulsen JS, Bottorff JL, Hayden MR. Factors associated with experiences of genetic discrimination among individuals at risk for Huntington disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 156: 19-27. PMID 21184581 DOI: 10.1002/Ajmg.B.31130  1
2011 Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, Christie BR. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiology of Disease. 41: 249-60. PMID 20875859 DOI: 10.1016/J.Nbd.2010.09.012  1
2011 Sowers JR, Whaley-Connell A, Hayden MR. The role of overweight and obesity in the cardiorenal syndrome Cardiorenal Medicine. 1: 5-12. DOI: 10.1159/000322822  1
2011 Bombard Y, Hayden MR. An interaction of genes in our social environment: Genetic discrimination among persons at risk for huntington disease Challenging Genetic Determinism: New Perspectives On the Gene in Its Multiple Environments. 182-203.  1
2010 Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, Metzler M, Bissada N, Wang L, Faull RL, Gray M, Yang XW, Raymond LA, Hayden MR. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 15019-29. PMID 21068307 DOI: 10.1523/Jneurosci.2071-10.2010  1
2010 Sturrock A, Laule C, Decolongon J, Dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 75: 1702-10. PMID 21060093 DOI: 10.1212/Wnl.0B013E3181Fc27E4  1
2010 Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 14708-18. PMID 21048129 DOI: 10.1523/Jneurosci.1637-10.2010  1
2010 Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, Lu G, Leavitt BR, Hayden MR. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 14318-29. PMID 20980587 DOI: 10.1523/Jneurosci.1589-10.2010  1
2010 Loo TT, Ross CJ, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC. Pharmacogenomics and active surveillance for serious adverse drug reactions in children. Pharmacogenomics. 11: 1269-85. PMID 20860467 DOI: 10.2217/Pgs.10.111  1
2010 Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics. 126: e986-9. PMID 20837591 DOI: 10.1542/Peds.2009-1907  1
2010 Madadi P, Joly Y, Avard D, Chitayat DC, Smith MA, Ross CJ, Carleton BC, Hayden MR, Koren G. Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits. Clinical Pharmacology and Therapeutics. 88: 792-5. PMID 20739920 DOI: 10.1038/Clpt.2010.125  1
2010 Sowers KM, Hayden MR. Calcific uremic arteriolopathy: Pathophysiology, reactive oxygen species and therapeutic approaches Oxidative Medicine and Cellular Longevity. 3: 109-121. PMID 20716935 DOI: 10.4161/oxim.3.2.11354  1
2010 Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O, MacDonald M, Wellington C, DiDonato S, Hayden M, Cattaneo E. Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 10844-50. PMID 20702713 DOI: 10.1523/Jneurosci.0917-10.2010  1
2010 Huang K, Kang MH, Askew C, Kang R, Sanders SS, Wan J, Davis NG, Hayden MR. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 40: 207-15. PMID 20685337 DOI: 10.1016/J.Nbd.2010.05.027  1
2010 Kang MH, Singaraja R, Hayden MR. Adenosine-triphosphate-binding cassette transporter-1 trafficking and function Trends in Cardiovascular Medicine. 20: 41-49. PMID 20656214 DOI: 10.1016/J.Tcm.2010.03.006  1
2010 Hayden MR, Goldsmith DJ. Sodium thiosulfate: new hope for the treatment of calciphylaxis. Seminars in Dialysis. 23: 258-62. PMID 20636917 DOI: 10.1111/j.1525-139X.2010.00738.x  1
2010 Ross CJD, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR, CPNDS Consortium. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid : Official Journal of the American Thyroid Association. 20: 681-687. PMID 20578893 DOI: 10.1089/Thy.2010.1642  1
2010 Williams JK, Erwin C, Juhl AR, Mengeling M, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS. In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1150-9. PMID 20468062 DOI: 10.1002/Ajmg.B.31080  1
2010 Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS. Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1081-93. PMID 20468061 DOI: 10.1002/Ajmg.B.31079  1
2010 Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence β-cell function in type 2 diabetes mellitus Current Opinion in Lipidology. 21: 178-185. PMID 20463468 DOI: 10.1097/Mol.0B013E328339387B  1
2010 Brunham LR, Kruit JK, Hayden MR, Verchere CB. Cholesterol in β-cell dysfunction: The emerging connection between HDL cholesterol and type 2 diabetes Current Diabetes Reports. 10: 55-60. PMID 20425068 DOI: 10.1007/S11892-009-0090-X  1
2010 Acuña-Alonzo V, Flores-Dorantes T, Kruit JK, Villarreal-Molina T, Arellano-Campos O, Hünemeier T, Moreno-Estrada A, Ortiz-López MG, Villamil-Ramírez H, León-Mimila P, Villalobos-Comparan M, Jacobo-Albavera L, Ramírez-Jiménez S, Sikora M, Zhang LH, ... ... Hayden MR, et al. A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Human Molecular Genetics. 19: 2877-85. PMID 20418488 DOI: 10.1093/Hmg/Ddq173  1
2010 Ding YL, Wang YH, Huang W, Liu G, Ross C, Hayden MR, Yang JK. Glucose intolerance and decreased early insulin response in mice with severe hypertriglyceridemia. Experimental Biology and Medicine (Maywood, N.J.). 235: 40-6. PMID 20404017 DOI: 10.1258/Ebm.2009.009100  1
2010 Chung S, Timmins JM, Duong M, Degirolamo C, Rong S, Sawyer JK, Singaraja RR, Hayden MR, Maeda N, Rudel LL, Shelness GS, Parks JS. Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism. The Journal of Biological Chemistry. 285: 12197-209. PMID 20178985 DOI: 10.1074/Jbc.M109.096933  1
2010 Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 65: 178-90. PMID 20152125 DOI: 10.1016/J.Neuron.2010.01.008  1
2010 Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Human Molecular Genetics. 19: 1528-38. PMID 20097678 DOI: 10.1093/Hmg/Ddq026  1
2010 Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, Hayden MR, Leavitt BR. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Human Molecular Genetics. 19: 1438-52. PMID 20089533 DOI: 10.1093/Hmg/Ddq018  1
2010 Olivecrona G, Ehrenborg E, Semb H, Makoveichuk E, Lindberg A, Hayden MR, Gin P, Davies BS, Weinstein MM, Fong LG, Beigneux AP, Young SG, Olivecrona T, Hernell O. Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. Journal of Lipid Research. 51: 1535-45. PMID 20026666 DOI: 10.1194/Jlr.M002717  1
2010 Wiens MO, Son WK, Ross C, Hayden M, Carleton B. Cases: Cocaine adulterant linked to neutropenia. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 182: 57-9. PMID 19969562 DOI: 10.1503/Cmaj.090286  1
2010 Glier MB, Pissios P, Babich SL, Macdonald ML, Hayden MR, Maratos-Flier E, Gibson WT. The metabolic phenotype of SCD1-deficient mice is independent of melanin-concentrating hormone. Peptides. 31: 123-9. PMID 19883709 DOI: 10.1016/J.Peptides.2009.10.018  1
2010 Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 397-408. PMID 19548255 DOI: 10.1002/Ajmg.B.30992  1
2010 Semaka A, Collins JA, Hayden MR. Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 314-20. PMID 19455596 DOI: 10.1002/Ajmg.B.30970  1
2010 Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RWY, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice (DOI:10.1016/j.neuron.2010.01.008) Neuron. 65: 436. DOI: 10.1016/j.neuron.2010.01.031  1
2010 Kruit JK, Brunham LR, Verchere CB, Hayden MR. Cholesterol toxicity in pancreatic islets from LDL receptor-deficient mice. Reply to: De Souza JC, de Oliveira CAM, Carneiro em et al. [letter] Diabetologia. 53: 2463-2464. DOI: 10.1007/S00125-010-1877-7  1
2009 Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. The Journal of Cell Biology. 187: 1083-99. PMID 20026656 DOI: 10.1083/Jcb.200909067  1
2009 Warby SC, Visscher H, Butland S, Pearson CE, Hayden MR. Response to Falush: a role for cis-element polymorphisms in HD. American Journal of Human Genetics. 85: 942-5. PMID 20004773 DOI: 10.1016/J.Ajhg.2009.11.006  1
2009 Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine. 15: 1407-13. PMID 19915593 DOI: 10.1038/Nm.2056  1
2009 Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics. 41: 1345-9. PMID 19898482 DOI: 10.1038/Ng.478  1
2009 Fan J, Cowan CM, Zhang LY, Hayden MR, Raymond LA. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 10928-38. PMID 19726651 DOI: 10.1523/Jneurosci.2491-09.2009  1
2009 Macdonald ML, Bissada N, Vallance BA, Hayden MR. Absence of stearoyl-CoA desaturase-1 does not promote DSS-induced acute colitis. Biochimica Et Biophysica Acta. 1791: 1166-72. PMID 19695343 DOI: 10.1016/J.Bbalip.2009.08.001  1
2009 Visscher H, Ross CJ, Dubé MP, Brown AM, Phillips MS, Carleton BC, Hayden MR. Application of principal component analysis to pharmacogenomic studies in Canada. The Pharmacogenomics Journal. 9: 362-72. PMID 19652663 DOI: 10.1038/Tpj.2009.36  1
2009 Singaraja RR, Kang MH, Vaid K, Sanders SS, Vilas GL, Arstikaitis P, Coutinho J, Drisdel RC, El-Husseini Ael D, Green WN, Berthiaume L, Hayden MR. Palmitoylation of ATP-binding cassette transporter A1 is essential for its trafficking and function. Circulation Research. 105: 138-47. PMID 19556522 DOI: 10.1161/Circresaha.108.193011  1
2009 Bombard Y, Veenstra G, Friedman JM, Creighton S, Currie L, Paulsen JS, Bottorff JL, Hayden MR. Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. Bmj (Clinical Research Ed.). 338: b2175. PMID 19509425 DOI: 10.1136/Bmj.B2175  1
2009 Xian X, Ding Y, Zhang L, Wang Y, McNutt MA, Ross C, Hayden MR, Deng X, Liu G. Enhanced atherothrombotic formation after oxidative injury by FeCl3 to the common carotid artery in severe combined hyperlipidemic mice. Biochemical and Biophysical Research Communications. 385: 563-9. PMID 19481534 DOI: 10.1016/J.Bbrc.2009.05.101  1
2009 Yeretssian G, Doiron K, Shao W, Leavitt BR, Hayden MR, Nicholson DW, Saleh M. Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proceedings of the National Academy of Sciences of the United States of America. 106: 9016-20. PMID 19447924 DOI: 10.1073/Pnas.0813362106  1
2009 Xian X, Liu T, Yu J, Wang Y, Miao Y, Zhang J, Yu Y, Ross C, Karasinska JM, Hayden MR, Liu G, Chui D. Presynaptic defects underlying impaired learning and memory function in lipoprotein lipase-deficient mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 4681-5. PMID 19357293 DOI: 10.1523/Jneurosci.0297-09.2009  1
2009 Huang K, Sanders S, Singaraja R, Orban P, Cijsouw T, Arstikaitis P, Yanai A, Hayden MR, El-Husseini A. Neuronal palmitoyl acyl transferases exhibit distinct substrate specificity Faseb Journal. 23: 2605-2615. PMID 19299482 DOI: 10.1096/Fj.08-127399  1
2009 Karasinska JM, Rinninger F, Lütjohann D, Ruddle P, Franciosi S, Kruit JK, Singaraja RR, Hirsch-Reinshagen V, Fan J, Brunham LR, Bissada N, Ramakrishnan R, Wellington CL, Parks JS, Hayden MR. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function Journal of Neuroscience. 29: 3579-3589. PMID 19295162 DOI: 10.1523/Jneurosci.4741-08.2009  1
2009 Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR. Mouse models of Huntington disease: Variations on a theme Dmm Disease Models and Mechanisms. 2: 123-129. PMID 19259385 DOI: 10.1242/Dmm.002451  1
2009 Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. American Journal of Human Genetics. 84: 351-66. PMID 19249009 DOI: 10.1016/J.Ajhg.2009.02.003  1
2009 Joshi PR, Wu NP, André VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2414-27. PMID 19244517 DOI: 10.1523/Jneurosci.5687-08.2009  1
2009 Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2193-204. PMID 19228972 DOI: 10.1523/Jneurosci.5473-08.2009  1
2009 Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain : a Journal of Neurology. 132: 919-32. PMID 19224899 DOI: 10.1093/Brain/Awp006  1
2009 Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, D'Ambola J, Hou Z, Liang Y, Poirier MA, Hirschhorn RR, Graham R, Hayden MR, Cole RN, Ross CA. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. The Journal of Biological Chemistry. 284: 10855-67. PMID 19204007 DOI: 10.1074/Jbc.M804813200  1
2009 Brunham LR, Singaraja RR, Duong M, Timmins JM, Fievet C, Bissada N, Kang MH, Samra A, Fruchart JC, McManus B, Staels B, Parks JS, Hayden MR. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 29: 548-54. PMID 19201688 DOI: 10.1161/Atvbaha.108.182303  1
2009 Vaessen SF, Dallinga-Thie GM, Ross CJ, Splint LJ, Castellani LW, Rensen PC, Hayden MR, Schaap FG, Kuivenhoven JA. Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels. Journal of Lipid Research. 50: 880-4. PMID 19141870 DOI: 10.1194/Jlr.M800551-Jlr200  1
2009 MacDonald ML, van Eck M, Hildebrand RB, Wong BW, Bissada N, Ruddle P, Kontush A, Hussein H, Pouladi MA, Chapman MJ, Fievet C, van Berkel TJ, Staels B, McManus BM, Hayden MR. Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 29: 341-7. PMID 19095997 DOI: 10.1161/Atvbaha.108.181099  1
2009 Bartha I, Dinya T, Seres I, Paragh G, Ross C, Hayden MR, Biró S, Vargha G. Acute hypertriglyceridemic pancreatitis during pregnancy due to homozygous lipoprotein lipase gene mutation. Clinica Chimica Acta; International Journal of Clinical Chemistry. 400: 137-8. PMID 19000906 DOI: 10.1016/J.Cca.2008.10.016  1
2009 Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Molecular and Cellular Neurosciences. 40: 121-7. PMID 18992820 DOI: 10.1016/J.Mcn.2008.09.007  1
2009 Wang Y, Sternfeld L, Yang F, Rodriguez JA, Ross C, Hayden MR, Carriere F, Liu G, Hofer W, Schulz I. Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells Gut. 58: 422-430. PMID 18936103 DOI: 10.1136/Gut.2007.146258  1
2009 Frohlich J, Hoag G, McLEOD R, Hayden M, Godin DV, Wadsworth LD, Critchley JD, Pritchard PH. Hypoalphalipoproteinemia resembling fish eye disease. Acta Medica Scandinavica. 221: 291-298. PMID 3591467 DOI: 10.1111/J.0954-6820.1987.Tb00896.X  1
2009 Szkody P, Anderson SF, Hayden M, Kronberg M, McGurk R, Riecken T, Schmidt GD, West AA, Gänsicke BT, Gomez-Moran AN, Schneider DP, Schreiber MR, Schwope AD. Cataclysmic variables from SDSS. VII. The seventh year (2006) Astronomical Journal. 137: 4011-4019. DOI: 10.1088/0004-6256/137/4/4011  1
2008 Cowan CM, Fan MM, Fan J, Shehadeh J, Zhang LY, Graham RK, Hayden MR, Raymond LA. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 12725-35. PMID 19036965 DOI: 10.1523/Jneurosci.4619-08.2008  1
2008 Brunham LR, Kastelein JJP, Hayden MR. ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease Jama - Journal of the American Medical Association. 300: 1997-1998. PMID 18984885 DOI: 10.1001/Jama.2008.539  1
2008 Hayden MR, Sowers JR. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus Journal of the Cardiometabolic Syndrome. 3: 129-131. PMID 18983326 DOI: 10.1111/j.1559-4572.2008.00006.x  1
2008 Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross C, Aronica E, High KA, Levi MM, Hayden MR, Kastelein JJ, Kuivenhoven JA. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arteriosclerosis, Thrombosis, and Vascular Biology. 28: 2303-4. PMID 18802015 DOI: 10.1161/Atvbaha.108.175620  1
2008 Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine. 205: 1869-77. PMID 18625748 DOI: 10.1084/Jem.20080178  1
2008 Addison S, Stas S, Hayden MR, Sowers JR. Insulin resistance and blood pressure Current Hypertension Reports. 10: 319-325. PMID 18625163 DOI: 10.1007/s11906-008-0059-1  1
2008 Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, Li S, Chan AW, Li XJ. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Human Molecular Genetics. 17: 2738-51. PMID 18558632 DOI: 10.1093/Hmg/Ddn175  1
2008 Semaka A, Warby S, Leavitt BR, Hayden MR. Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1794-5; author reply. PMID 18548612 DOI: 10.1002/mds.21820  1
2008 Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiology of Disease. 31: 80-8. PMID 18502655 DOI: 10.1016/J.Nbd.2008.03.010  1
2008 Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, Singaraja RR, Overall CM, Hayden MR. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Human Molecular Genetics. 17: 2390-404. PMID 18445618 DOI: 10.1093/Hmg/Ddn139  1
2008 Lerch JP, Carroll JB, Dorr A, Spring S, Evans AC, Hayden MR, Sled JG, Henkelman RM. Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. Neuroimage. 41: 243-51. PMID 18387826 DOI: 10.1016/J.Neuroimage.2008.02.019  1
2008 Hayden MR, Goldsmith D, Sowers JR, Khanna R. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate International Urology and Nephrology. 40: 443-451. PMID 18369733 DOI: 10.1007/s11255-008-9373-4  1
2008 Hayden MR. Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors Journal of the Cardiometabolic Syndrome. 3: 70-71. PMID 18326982 DOI: 10.1111/j.1559-4572.2008.07787.x  1
2008 Hayden MR. Calciphylaxis and the cardiometabolic syndrome: the emerging role of sodium thiosulfate as a novel treatment option Journal of the Cardiometabolic Syndrome. 3: 55-59. PMID 18326977 DOI: 10.1111/j.1559-4572.2008.08261.x  1
2008 Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes Journal of Clinical Investigation. 118: 403-408. PMID 18246189 DOI: 10.1172/Jci33296  1
2008 Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, ... Hayden M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery, and Psychiatry. 79: 874-80. PMID 18096682 DOI: 10.1136/Jnnp.2007.128728  1
2008 Zhang X, Qi R, Xian X, Yang F, Blackstein M, Deng X, Fan J, Ross C, Karasinska J, Hayden MR, Liu G. Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circulation Research. 102: 250-6. PMID 18032735 DOI: 10.1161/Circresaha.107.156554  1
2008 Fan MM, Zhang H, Hayden MR, Pelech SL, Raymond LA. Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors. Journal of Neurochemistry. 104: 790-805. PMID 17971125 DOI: 10.1111/J.1471-4159.2007.05016.X  1
2008 MacDonald ML, Singaraja RR, Bissada N, Ruddle P, Watts R, Karasinska JM, Gibson WT, Fievet C, Vance JE, Staels B, Hayden MR. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. Journal of Lipid Research. 49: 217-29. PMID 17960025 DOI: 10.1194/Jlr.M700478-Jlr200  1
2008 Bombard Y, Penziner E, Suchowersky O, Guttman M, Paulsen JS, Bottorff JL, Hayden MR. Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. European Journal of Human Genetics : Ejhg. 16: 279-89. PMID 17957229 DOI: 10.1038/Sj.Ejhg.5201937  1
2008 Penziner E, Williams JK, Erwin C, Bombard Y, Wallis A, Beglinger LJ, Hayden MR, Paulsen JS. Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 147: 320-5. PMID 17948904 DOI: 10.1002/Ajmg.B.30600  1
2008 Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM. Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage. 39: 32-9. PMID 17942324 DOI: 10.1016/J.Neuroimage.2007.08.033  1
2008 Liu G, Hayden MR. Response to the letter by Ebara et al Circulation Research. 102. DOI: 10.1161/Circresaha.108.178715  1
2008 Hayden MR, Sowers JR. Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome Journal of the American Society of Hypertension. 2: 239-266. DOI: 10.1016/j.jash.2007.12.002  1
2008 Karuparthi PR, Yerram P, Govindarajan G, Hayden MR. Obesity and cardiovascular risk Current Cardiovascular Risk Reports. 2: 113-119. DOI: 10.1007/s12170-008-0022-3  1
2007 Orban P, Devon RS, Hayden MR, Leavitt BR. Chapter 15 Juvenile amyotrophic lateral sclerosis. Handbook of Clinical Neurology. 82: 301-12. PMID 18808900 DOI: 10.1016/S0072-9752(07)80018-2  1
2007 Ratovitski T, Nakamura M, D'Ambola J, Chighladze E, Liang Y, Wang W, Graham R, Hayden MR, Borchelt DR, Hirschhorn RR, Ross CA. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle (Georgetown, Tex.). 6: 2970-81. PMID 18156806 DOI: 10.4161/Cc.6.23.4992  1
2007 Fernandes HB, Baimbridge KG, Church J, Hayden MR, Raymond LA. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 13614-23. PMID 18077673 DOI: 10.1523/Jneurosci.3455-07.2007  1
2007 Delcour KS, Tejwani L, Hayden MR, Govindarajan G. Intraventricular mechanical asynchrony in asymptomatic morbidly obese individuals Journal of the Cardiometabolic Syndrome. 2: 305-308. PMID 18059217 DOI: 10.1111/j.1559-4564.2007.07741.x  1
2007 Parker JA, Metzler M, Georgiou J, Mage M, Roder JC, Rose AM, Hayden MR, Néri C. Huntingtin-interacting protein 1 influences worm and mouse presynaptic function and protects Caenorhabditis elegans neurons against mutant polyglutamine toxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 11056-64. PMID 17928447 DOI: 10.1523/Jneurosci.1941-07.2007  1
2007 Gibson WT, Hayden MR. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Annals of the New York Academy of Sciences. 1110: 209-21. PMID 17911436 DOI: 10.1196/Annals.1423.023  1
2007 Ross CJ, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR. Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children. Annals of the New York Academy of Sciences. 1110: 177-92. PMID 17911433 DOI: 10.1196/Annals.1423.020  1
2007 Karuparthi PR, Yerram P, Gupta D, Hayden MR. High-cortisol states can masquerade as the cardiometabolic syndrome Journal of the Cardiometabolic Syndrome. 2: 223-226. PMID 17804949 DOI: 10.1111/j.1559-4564.2007.07304.x  1
2007 Sowers KM, Habibi J, Hayden MR. Diabetic nephropathy and tubulointerstitial fibrosis in cardiometabolic syndrome and type 2 diabetes mellitus Journal of the Cardiometabolic Syndrome. 2: 143-148. PMID 17684466 DOI: 10.1111/j.1559-4564.2007.06160.x  1
2007 Hayden MR. Islet amyloid and fibrosis in the cardiometabolic syndrome and type 2 diabetes mellitus Journal of the Cardiometabolic Syndrome. 2: 70-75. PMID 17684452 DOI: 10.1111/j.1559-4564.2007.06159.x  1
2007 Valenza M, Carroll JB, Leoni V, Bertram LN, Björkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human Molecular Genetics. 16: 2187-98. PMID 17613541 DOI: 10.1093/Hmg/Ddm170  1
2007 Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB, Ross CA, Nance M, Kayson E, Julian-Baros E, Hayden MR, Kieburtz K, Guttman M, Oakes D, Shoulson I, et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain : a Journal of Neurology. 130: 1732-44. PMID 17584778 DOI: 10.1093/Brain/Awm107  1
2007 Benn CL, Slow EJ, Farrell LA, Graham R, Deng Y, Hayden MR, Cha JH. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience. 147: 354-72. PMID 17544587 DOI: 10.1016/J.Neuroscience.2007.03.010  1
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/Hmg/Ddm133  1
2007 Butland SL, Devon RS, Huang Y, Mead CL, Meynert AM, Neal SJ, Lee SS, Wilkinson A, Yang GS, Yuen MM, Hayden MR, Holt RA, Leavitt BR, Ouellette BF. CAG-encoded polyglutamine length polymorphism in the human genome. Bmc Genomics. 8: 126. PMID 17519034 DOI: 10.1186/1471-2164-8-126  1
2007 Hayden MR, Sowers JR. Isletopathy in type 2 diabetes mellitus: Implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress Antioxidants and Redox Signaling. 9: 891-910. PMID 17516840 DOI: 10.1089/ars.2007.1610  1
2007 Hayden MR, Sowers JR. Redox imbalance in diabetes Antioxidants and Redox Signaling. 9: 865-867. PMID 17477794 DOI: 10.1089/ars.2007.1640  1
2007 Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B, Radomski C, Donaldson G, Ives E, Cox J, ... ... Hayden MR, et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clinical Genetics. 71: 311-9. PMID 17470132 DOI: 10.1111/j.1399-0004.2007.00790.x  1
2007 Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y. When good drugs go bad. Nature. 446: 975-7. PMID 17460642 DOI: 10.1038/446975A  1
2007 Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR, Leavitt BR. Testicular degeneration in Huntington disease. Neurobiology of Disease. 26: 512-20. PMID 17433700 DOI: 10.1016/J.Nbd.2007.01.006  1
2007 Ross CJ, Katzov H, Carleton B, Hayden MR. Pharmacogenomics and its implications for autoimmune disease. Journal of Autoimmunity. 28: 122-8. PMID 17418528 DOI: 10.1016/J.Jaut.2007.02.008  1
2007 Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 3768-79. PMID 17409241 DOI: 10.1523/Jneurosci.4356-06.2007  1
2007 Van Raamsdonk JM, Warby SC, Hayden MR. Selective degeneration in YAC mouse models of Huntington disease Brain Research Bulletin. 72: 124-131. PMID 17352936 DOI: 10.1016/J.Brainresbull.2006.10.018  1
2007 Metzler M, Gan L, Wong TP, Liu L, Helm J, Liu L, Georgiou J, Wang Y, Bissada N, Cheng K, Roder JC, Wang YT, Hayden MR. NMDA receptor function and NMDA receptor-dependent phosphorylation of huntingtin is altered by the endocytic protein HIP1. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 2298-308. PMID 17329427 DOI: 10.1523/Jneurosci.5175-06.2007  1
2007 Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nature Medicine. 13: 340-7. PMID 17322896 DOI: 10.1038/Nm1546  1
2007 Bombard Y, Penziner E, Decolongon J, Klimek ML, Creighton S, Suchowersky O, Guttman M, Paulsen JS, Bottorff JL, Hayden MR. Managing genetic discrimination: strategies used by individuals found to have the Huntington disease mutation. Clinical Genetics. 71: 220-31. PMID 17309644 DOI: 10.1111/J.1399-0004.2007.00770.X  1
2007 Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, Ross CA, Beglinger L, Hayden MR, Kieburtz K, Kayson E, Julian-Baros E, Duff K, Guttman M, Nance M, et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia. 45: 1767-76. PMID 17303196 DOI: 10.1016/J.Neuropsychologia.2006.12.015  1
2007 Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease. 26: 189-200. PMID 17276692 DOI: 10.1016/J.Nbd.2006.12.010  1
2007 Hirsch-Reinshagen V, Chan JY, Wilkinson A, Tanaka T, Fan J, Ou G, Maia LF, Singaraja RR, Hayden MR, Wellington CL. Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-β peptide levels in vivo Journal of Lipid Research. 48: 914-923. PMID 17235115 DOI: 10.1194/Jlr.M600543-Jlr200  1
2007 Andresen JM, Gayán J, Djoussé L, Roberts S, Brocklebank D, Cherny SS, Cardon LR, Gusella JF, MacDonald ME, Myers RH, Housman DE, Wexler NS. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Annals of Human Genetics. 71: 295-301. PMID 17181545 DOI: 10.1111/J.1469-1809.2006.00335.X  1
2007 Wang J, Xian X, Huang W, Chen L, Wu L, Zhu Y, Fan J, Ross C, Hayden MR, Liu G. Expression of LPL in endothelial-intact artery results in lipid deposition and vascular cell adhesion molecule-1 upregulation in both LPL and ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 27: 197-203. PMID 17038632 DOI: 10.1161/01.Atv.0000249683.80414.D9  1
2007 Khatchadourian K, Smith CE, Metzler M, Gregory M, Hayden MR, Cyr DG, Hermo L. Structural abnormalities in spermatids together with reduced sperm counts and motility underlie the reproductive defect in HIP1-/- mice. Molecular Reproduction and Development. 74: 341-59. PMID 16967501 DOI: 10.1002/Mrd.20564  1
2006 Hayden MR, Chowdhury NA, Witte L, Sowers JR. Microalbuminuria and proximal tubule remodeling in the cardiometabolic syndrome Journal of the Cardiometabolic Syndrome. 1: 107-114. PMID 17679822 DOI: 10.1111/j.1559-4564.2006.05625.x  1
2006 Hayden MR. Atherogenic dyslipidemia Journal of the Cardiometabolic Syndrome. 1: 166-167. PMID 17679821  1
2006 Karuparthi PR, Yerram P, Hayden MR. Diastolic dysfunction in the cardiometabolic syndrome Journal of the Cardiometabolic Syndrome. 1: 369-372. PMID 17679796 DOI: 10.1111/j.1559-4564.2006.06049.x  1
2006 Hayden MR, Stump CS, Sowers JR. Introduction: organ involvement in the cardiometabolic syndrome Journal of the Cardiometabolic Syndrome. 1: 16-24. PMID 17675904 DOI: 10.1111/j.0197-3118.2006.05454.x  1
2006 Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome Journal of the Cardiometabolic Syndrome. 1: 36-40. PMID 17675901 DOI: 10.1111/j.0197-3118.2006.05523.x  1
2006 Lastra G, Manrique CM, Hayden MR. The role of beta-cell dysfunction in the cardiometabolic syndrome Journal of the Cardiometabolic Syndrome. 1: 41-46. PMID 17675900 DOI: 10.1111/j.0197-3118.2006.05458.x  1
2006 Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. Bmc Neuroscience. 7: 80. PMID 17147801 DOI: 10.1186/1471-2202-7-80  1
2006 Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR, Friedlander RM. Huntingtin inhibits caspase-3 activation. The Embo Journal. 25: 5896-906. PMID 17124493 DOI: 10.1038/Sj.Emboj.7601445  1
2006 Oliveira JM, Chen S, Almeida S, Riley R, Gonçalves J, Oliveira CR, Hayden MR, Nicholls DG, Ellerby LM, Rego AC. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 11174-86. PMID 17065457 DOI: 10.1523/Jneurosci.3004-06.2006  1
2006 Houde C, Dickinson RJ, Houtzager VM, Cullum R, Montpetit R, Metzler M, Simpson EM, Roy S, Hayden MR, Hoodless PA, Nicholson DW. Hippi is essential for node cilia assembly and Sonic hedgehog signaling. Developmental Biology. 300: 523-33. PMID 17027958 DOI: 10.1016/J.Ydbio.2006.09.001  1
2006 Leavitt BR, Hayden MR. Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease? Nature Clinical Practice. Neurology. 2: 536-7. PMID 16990826 DOI: 10.1038/Ncpneuro0299  1
2006 Semaka A, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clinical Genetics. 70: 283-94. PMID 16965319 DOI: 10.1111/J.1399-0004.2006.00668.X  0.4
2006 Kishikawa S, Li JL, Gillis T, Hakky MM, Warby S, Hayden M, MacDonald ME, Myers RH, Gusella JF. Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. Neurobiology of Disease. 24: 280-5. PMID 16962786 DOI: 10.1016/J.Nbd.2006.07.008  1
2006 Singaraja RR, Van Eck M, Bissada N, Zimetti F, Collins HL, Hildebrand RB, Hayden A, Brunham LR, Kang MH, Fruchart JC, Van Berkel TJ, Parks JS, Staels B, Rothblat GH, Fiévet C, ... Hayden MR, et al. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation. 114: 1301-9. PMID 16940190 DOI: 10.1161/Circulationaha.106.621433  1
2006 Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross CA, Margolis RL, Rosenblatt A, Squitieri F, Frati L, Gómez-Tortosa E, García CA, Suchowersky O, Klimek ML, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. Bmc Medical Genetics. 7: 71. PMID 16914060 DOI: 10.1186/1471-2350-7-71  1
2006 Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiology of Disease. 24: 114-27. PMID 16899370 DOI: 10.1016/J.Nbd.2006.06.007  1
2006 Alvarez C, Tredwell S, Vera MD, Hayden M. The genotype-phenotype correlation of hereditary multiple exostoses. Clinical Genetics. 70: 122-130. PMID 16879194 DOI: 10.1111/J.1399-0004.2006.00653.X  0.01
2006 Singaraja RR, Visscher H, James ER, Chroni A, Coutinho JM, Brunham LR, Kang MH, Zannis VI, Chimini G, Hayden MR. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circulation Research. 99: 389-97. PMID 16873719 DOI: 10.1161/01.Res.0000237920.70451.Ad  1
2006 Björkqvist M, Petersén A, Nielsen J, Ecker D, Mulder H, Hayden MR, Landwehrmeyer B, Brundin P, Leavitt BR. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clinical Genetics. 70: 78-9. PMID 16813610 DOI: 10.1111/J.1399-0004.2006.00636.X  1
2006 Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends in Genetics : Tig. 22: 408-11. PMID 16806565 DOI: 10.1016/J.Tig.2006.05.008  1
2006 Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, ... ... Hayden MR, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 125: 1179-91. PMID 16777606 DOI: 10.1016/J.Cell.2006.04.026  1
2006 Devon RS, Orban PC, Gerrow K, Barbieri MA, Schwab C, Cao LP, Helm JR, Bissada N, Cruz-Aguado R, Davidson TL, Witmer J, Metzler M, Lam CK, Tetzlaff W, Simpson EM, ... ... Hayden MR, et al. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proceedings of the National Academy of Sciences of the United States of America. 103: 9595-600. PMID 16769894 DOI: 10.1073/Pnas.0510197103  1
2006 Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E. Preparing for preventive clinical trials: the Predict-HD study. Archives of Neurology. 63: 883-90. PMID 16769871 DOI: 10.1001/Archneur.63.6.883  1
2006 Brunham LR, Singaraja RR, Hayden MR. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis Annual Review of Nutrition. 26: 105-129. PMID 16704350 DOI: 10.1146/Annurev.Nutr.26.061505.111214  1
2006 Yanai A, Huang K, Kang R, Singaraja RR, Arstikaitis P, Gan L, Orban PC, Mullard A, Cowan CM, Raymond LA, Drisdel RC, Green WN, Ravikumar B, Rubinsztein DC, El-Husseini A, ... Hayden MR, et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nature Neuroscience. 9: 824-31. PMID 16699508 DOI: 10.1038/Nn1702  1
2006 Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease. 23: 190-7. PMID 16697652 DOI: 10.1016/J.Nbd.2006.02.011  1
2006 Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. Body weight is modulated by levels of full-length huntingtin. Human Molecular Genetics. 15: 1513-23. PMID 16571604 DOI: 10.1093/Hmg/Ddl072  1
2006 Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. The Journal of Clinical Investigation. 116: 1052-62. PMID 16543947 DOI: 10.1172/Jci27352  1
2006 Bae BI, Hara MR, Cascio MB, Wellington CL, Hayden MR, Ross CA, Ha HC, Li XJ, Snyder SH, Sawa A. Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proceedings of the National Academy of Sciences of the United States of America. 103: 3405-9. PMID 16492755 DOI: 10.1073/Pnas.0511316103  1
2006 Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR, Van Berkel TJ. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 26: 929-34. PMID 16456089 DOI: 10.1161/01.Atv.0000208364.22732.16  1
2006 Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR. Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry. 96: 1121-9. PMID 16417581 DOI: 10.1111/J.1471-4159.2005.03605.X  1
2006 Graham RK, Slow EJ, Deng Y, Bissada N, Lu G, Pearson J, Shehadeh J, Leavitt BR, Raymond LA, Hayden MR. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiology of Disease. 21: 444-55. PMID 16230019 DOI: 10.1016/J.Nbd.2005.08.007  1
2006 Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiology of Disease. 21: 392-403. PMID 16165367 DOI: 10.1016/J.Nbd.2005.08.001  1
2006 Leuven SIv, Kastelein JJP, Hayden MR, Stroes ES. Mycophenolate mofetil as an immunomodulatory silver bullet in atherogenesis Lupus. 15: 11-17. DOI: 10.1177/0961203306071670  1
2006 Hayden MR, Sowers JR. Hypertension in type 2 diabetes mellitus Insulin. 1: 22-37. DOI: 10.1016/S1557-0843(06)80005-9  1
2006 Hirsch-Reinshagen V, Chan JY, McIsaac SA, Naus KE, Maia LF, Burgess BL, Singaraja RR, Hayden MR, Wellington CL. P1-053: Alzheimer’s disease neuropathology is not mitigated by the physiological expression of human ABCA1 in APP/PS1 mice Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.428  1
2006 Pouladi MA, Bezprozvanny I, Raymond LA, Hayden MR. Molecular pathogenesis of Huntington's disease: The role of excitotoxicity Genetic Instabilities and Neurological Diseases, Second Edition. 251-260. DOI: 10.1016/B978-012369462-1/50016-8  1
2005 Brunham LR, Singaraja RR, Pape TD, Kejariwal A, Thomas PD, Hayden MR. Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. Plos Genetics. 1: e83. PMID 16429166 DOI: 10.1371/Journal.Pgen.0010083  1
2005 Hayden MR, Bombard Y. Psychosocial effects of predictive testing for Huntington's disease Advances in Neurology. 96: 226-239. PMID 16383222  1
2005 Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 3823-35. PMID 16278236 DOI: 10.1093/Hmg/Ddi407  1
2005 Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: Paying homage to the podocyte American Journal of Nephrology. 25: 553-569. PMID 16210838 DOI: 10.1159/000088810  1
2005 Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. The Journal of Biological Chemistry. 280: 43243-56. PMID 16207707 DOI: 10.1074/Jbc.M508781200  1
2005 Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry. 95: 210-20. PMID 16181425 DOI: 10.1111/J.1471-4159.2005.03357.X  1
2005 van Leuven SI, Kastelein JJ, Hayden MR, d'Cruz D, Hughes GR, Stroes ES. Cardiovascular disease in systemic lupus erythematosus: has the time for action come? Current Opinion in Lipidology. 16: 501-6. PMID 16148533 DOI: 10.1097/01.Mol.0000182533.19135.Cb  1
2005 Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Journal of Neurochemistry. 95: 553-62. PMID 16135087 DOI: 10.1111/J.1471-4159.2005.03411.X  1
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology. 196: 266-72. PMID 16129433 DOI: 10.1016/J.Expneurol.2005.07.021  1
2005 Kegel KB, Sapp E, Yoder J, Cuiffo B, Sobin L, Kim YJ, Qin ZH, Hayden MR, Aronin N, Scott DL, Isenberg G, Goldmann WH, DiFiglia M. Huntingtin associates with acidic phospholipids at the plasma membrane. The Journal of Biological Chemistry. 280: 36464-73. PMID 16085648 DOI: 10.1074/Jbc.M503672200  1
2005 Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proceedings of the National Academy of Sciences of the United States of America. 102: 11402-7. PMID 16076956 DOI: 10.1073/Pnas.0503634102  1
2005 Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 65: 286-92. PMID 16043801 DOI: 10.1212/01.Wnl.0000169025.09670.6D  1
2005 Ross CJ, Liu G, Kuivenhoven JA, Twisk J, Rip J, van Dop W, Excoffon KJ, Lewis SM, Kastelein JJ, Hayden MR. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arteriosclerosis, Thrombosis, and Vascular Biology. 25: 2143-50. PMID 16002740 DOI: 10.1161/01.Atv.0000176971.27302.B0  1
2005 Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of Neurochemistry. 94: 1087-101. PMID 15992377 DOI: 10.1111/J.1471-4159.2005.03255.X  1
2005 Hayden MR, Sowers JR, Tyagi SC. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: The matrix preloaded Cardiovascular Diabetology. 4. PMID 15985157 DOI: 10.1186/1475-2840-4-9  1
2005 Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 4169-80. PMID 15843620 DOI: 10.1523/Jneurosci.0590-05.2005  1
2005 Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, Crocker SF, Robertson HA, Hayden MR. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Human Molecular Genetics. 14: 1569-77. PMID 15843398 DOI: 10.1093/Hmg/Ddi165  1
2005 Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. The Journal of Clinical Investigation. 115: 1333-42. PMID 15841208 DOI: 10.1172/Jci23915  1
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 1379-92. PMID 15829505 DOI: 10.1093/Hmg/Ddi147  1
2005 Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinás R, Kristal BS, Hayden MR, Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 102: 2602-7. PMID 15695335 DOI: 10.1073/Pnas.0409402102  1
2005 Devon RS, Schwab C, Topp JD, Orban PC, Yang YZ, Pape TD, Helm JR, Davidson TL, Rogers DA, Gros-Louis F, Rouleau G, Horazdovsky BF, Leavitt BR, Hayden MR. Cross-species characterization of the ALS2 gene and analysis of its pattern of expression in development and adulthood. Neurobiology of Disease. 18: 243-57. PMID 15686953 DOI: 10.1016/J.Nbd.2004.10.002  1
2005 Hayden MR, Tyagi SC. Isolated low high density lipoprotein-cholesterol (HDL-C): Implications of global risk reduction. Case report and systematic scientific review Cardiovascular Diabetology. 4. PMID 15631632 DOI: 10.1186/1475-2840-4-1  1
2005 Legendre-Guillemin V, Metzler M, Lemaire JF, Philie J, Gan L, Hayden MR, McPherson PS. Huntingtin interacting protein 1 (HIP1) regulates clathrin assembly through direct binding to the regulatory region of the clathrin light chain. The Journal of Biological Chemistry. 280: 6101-8. PMID 15533941 DOI: 10.1074/Jbc.M408430200  1
2005 Hayden MR, Biesecker B. Introduction to Social and Behavioural Research in genetics Clinical Genetics. 67: 480. DOI: 10.1111/J.1399-0004.2005.00464.X  1
2005 Berkel TV, Out R, Hoekstra M, Hildebrand RB, Kruijt K, Singaraja R, Kaminski WE, Schmitz G, Hayden M, Eck MV. W10-IS-001 Role of ABCA1 and SR-BI in cholesterol transport and atherosclerosis Atherosclerosis Supplements. 6: 46. DOI: 10.1016/S1567-5688(05)80183-7  1
2005 Rip J, Nierman MC, Sierts JA, Ross CJ, Hayden MR, Jong Ad, Dijkhuizen P, Hermens W, Twisk J, Kastelein JJ, Kuivenhoven JA, Meulenberg JM. 907. Gene Therapy for Genetic Lipoprotein Lipase (LPL) Deficiency; an Update Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.450  1
2005 Van Raamsdonk JM, Hayden MR, Leavitt BR. Experimental models of Huntington's disease Drug Discovery Today: Disease Models. 2: 291-297. DOI: 10.1016/J.Ddmod.2005.11.010  1
2005 Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 diabetes mellitus as a conformational disease Journal of the Pancreas. 6: 287-302.  1
2004 Shastry S, Tyagi N, Hayden MR, Tyagi SC. Proteomic analysis of homocysteine inhibition of microvascular endothelial cell angiogenesis Cellular and Molecular Biology (Noisy-Le-Grand, France). 50: 931-937. PMID 15704257  1
2004 Hayden MR. A primary care clinician's observations of the problem-based learning curriculum Missouri Medicine. 101: 541-543. PMID 15678997  1
2004 Huang K, Yanai A, Kang R, Arstikaitis P, Singaraja RR, Metzler M, Mullard A, Haigh B, Gauthier-Campbell C, Gutekunst CA, Hayden MR, El-Husseini A. Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins. Neuron. 44: 977-86. PMID 15603740 DOI: 10.1016/J.Neuron.2004.11.027  1
2004 Hayden MR, Tyagi SC. Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy Medical Science Monitor. 10. PMID 15567993  1
2004 Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O'Hearn E, Ross CA, Seltzer WK, Walker RH, Ashizawa T, Rasmussen A, Hayden M, Almqvist EW, Harris J, Fahn S, MacDonald ME, et al. Huntington's Disease-like 2 (HDL2) in North America and Japan. Annals of Neurology. 56: 670-4. PMID 15468075 DOI: 10.1002/Ana.20248  1
2004 Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JH, Petersen W, Dullaart RP, Stroes ES, Zwinderman AH, de Groot E, Hayden MR, Kuivenhoven JA, Kastelein JJ. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. Journal of the American College of Cardiology. 44: 1429-35. PMID 15464323 DOI: 10.1016/J.Jacc.2004.06.070  1
2004 Tang TS, Tu H, Orban PC, Chan EY, Hayden MR, Bezprozvanny I. HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca release in primary culture of striatal medium spiny neurons. The European Journal of Neuroscience. 20: 1779-87. PMID 15379999 DOI: 10.1111/J.1460-9568.2004.03633.X  1
2004 Trushina E, Dyer RB, Badger JD, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS, Van Houten B, Zeitlin S, McNiven M, Aebersold R, Hayden M, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Molecular and Cellular Biology. 24: 8195-209. PMID 15340079 DOI: 10.1128/Mcb.24.18.8195-8209.2004  1
2004 Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochemical and Biophysical Research Communications. 322: 1310-7. PMID 15336977 DOI: 10.1016/J.Bbrc.2004.08.035  1
2004 Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. The Journal of Biological Chemistry. 279: 41197-207. PMID 15269218 DOI: 10.1074/Jbc.M407962200  1
2004 Li L, Murphy TH, Hayden MR, Raymond LA. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. Journal of Neurophysiology. 92: 2738-46. PMID 15240759 DOI: 10.1152/Jn.00308.2004  1
2004 Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, Steinberg MH, Nolan V, Baldwin CT, Hotchkiss RS, Buchman TG, Zehnbauer BA, Hayden MR, Farrer LA, Roy S, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature. 429: 75-9. PMID 15129283 DOI: 10.1038/Nature02451  1
2004 Delatycki MB, Allen KJ, Gow P, MacFarlane J, Radomski C, Thompson J, Hayden MR, Goldberg YP, Samuels ME. A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. Clinical Genetics. 65: 378-83. PMID 15099344 DOI: 10.1111/J.0009-9163.2004.00254.X  1
2004 Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, ... ... Hayden MR, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics. 74: 1064-73. PMID 15060842 DOI: 10.1086/420795  1
2004 Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, Raymond LA. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Molecular and Cellular Neurosciences. 25: 469-79. PMID 15033175 DOI: 10.1016/J.Mcn.2003.11.014  1
2004 Djoussé L, Knowlton B, Hayden MR, Almqvist EW, Brinkman RR, Ross CA, Margolis RL, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics. 5: 109-14. PMID 15029481 DOI: 10.1007/S10048-004-0175-2  1
2004 Selva DM, Hirsch-Reinshagen V, Burgess B, Zhou S, Chan J, McIsaac S, Hayden MR, Hammond GL, Vogl AW, Wellington CL. The ATP-binding cassette transporter 1 mediates lipid efflux from Sertoli cells and influences male fertility. Journal of Lipid Research. 45: 1040-50. PMID 15026428 DOI: 10.1194/Jlr.M400007-Jlr200  1
2004 Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics. 65: 267-77. PMID 15025718 DOI: 10.1111/J.1399-0004.2004.00241.X  1
2004 Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. The Journal of Biological Chemistry. 279: 20211-20. PMID 14981075 DOI: 10.1074/Jbc.M401267200  1
2004 Hovingh GK, Kuivenhoven JA, Bisoendial RJ, Groen AK, Van Dam M, Van Tol A, Wellington C, Hayden MR, Smelt AHM, Kastelein JJP. HDL deficiency and atherosclerosis: Lessons from Tangier disease [1] Journal of Internal Medicine. 255: 299-301. PMID 14746569 DOI: 10.1046/J.0954-6820.2003.01256.X  1
2004 Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, Kegel KB, Aronin N, DiFiglia M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 269-81. PMID 14715959 DOI: 10.1523/Jneurosci.1409-03.2004  1
2004 Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, ... Hayden MR, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death and Differentiation. 11: 424-38. PMID 14713958 DOI: 10.1038/Sj.Cdd.4401358  1
2004 Zala D, Bensadoun JC, Pereira de Almeida L, Leavitt BR, Gutekunst CA, Aebischer P, Hayden MR, Déglon N. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Experimental Neurology. 185: 26-35. PMID 14697316 DOI: 10.1016/J.Expneurol.2003.09.002  1
2004 Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dubé MP, Andres L, MacFarlane J, Sakellaropoulos N, Politou M, Nemeth E, Thompson J, Risler JK, Zaborowska C, Babakaiff R, ... ... Hayden MR, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nature Genetics. 36: 77-82. PMID 14647275 DOI: 10.1038/Ng1274  1
2004 Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle Nutrition and Metabolism. 1. DOI: 10.1186/1743-7075-1-10  1
2004 Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation Nutrition Journal. 3. DOI: 10.1186/1475-2891-3-4  1
2004 Hayden MR, Tyagi SC. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: A malignant transformation Cardiovascular Diabetology. 3. DOI: 10.1186/1475-2840-3-1  1
2004 Brunham LR, Wellington CL, Orban PC, Deng Y, Hayden MR. 416 The Contribution Of Hepatic Adenosine Triphosphate-Binding Cassette Transporter, Abca1, To High-Density Lipoprotein Cholesterol Levels In Vivo. Journal of Investigative Medicine. 52. DOI: 10.1136/Jim-52-Suppl1-416  1
2004 Hirsch-Reinshagen V, Zhou S, Chan J, McIsaac S, Cohn J, Hayden M, Wellington C. O1-03-07 ABCA1 modulates APOE levels in brain and plasma Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)80050-2  1
2004 Ross CJD, Twisk J, Kuivenhoven JA, Liu G, Miao F, Oever Kvd, Beetz M, Verbart D, Bakker A, Oranje PPA, Hermens WT, Dijkhuizen P, Kastelein JJP, Meulenberg JJM, Hayden MR. 40. Correction of Dyslipidemia in Murine and Feline Models of Lipoprotein Lipase Deficiency by Intramuscular Administration of AAV1-LPLS447X Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.063  1
2004 Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O'Hearn E, Ross CA, Seltzer WK, Walker RH, Ashizawa T, Rasmussen A, Hayden M, Almqvist EW, Harris J, Fahn S, MacDonald ME, et al. Erratum: Huntington's disease-like 2 (HDL2) in North America and Japan (Annals of Neurology (November 2004) 56 (670-674)) Annals of Neurology. 56. DOI: 10.1002/Ana.20349  1
2003 Squitieri F, Almqvist EW, Cannella M, Cislaghi G, Hayden MR. Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene. Clinical Genetics. 64: 524-525. PMID 14986835 DOI: 10.1046/J.1399-0004.2003.00155.X  1
2003 Hand CK, Devon RS, Gros-Louis F, Rochefort D, Khoris J, Meininger V, Bouchard JP, Camu W, Hayden MR, Rouleau GA. Mutation screening of the ALS2 gene in sporadic and familial amyotrophic lateral sclerosis. Archives of Neurology. 60: 1768-71. PMID 14676054 DOI: 10.1001/Archneur.60.12.1768  1
2003 Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, Murphy TH, Raymond LA. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiology of Aging. 24: 1113-21. PMID 14643383 DOI: 10.1016/J.Neurobiolaging.2003.04.003  1
2003 Aylward EH, Rosenblatt A, Field K, Yallapragada V, Kieburtz K, McDermott M, Raymond LA, Almqvist EW, Hayden M, Ross CA. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Research Bulletin. 62: 137-41. PMID 14638387 DOI: 10.1016/J.Brainresbull.2003.09.005  1
2003 Brunham LR, Hayden MR. Clarity is essential when using Nucleotide number systems Atherosclerosis. 170: 349. PMID 14612218 DOI: 10.1016/S0021-9150(03)00234-X  1
2003 Almqvist EW, Brinkman RR, Wiggins S, Hayden MR. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clinical Genetics. 64: 300-9. PMID 12974735 DOI: 10.1034/J.1399-0004.2003.00157.X  1
2003 Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, Leavitt BR, Cattaneo E, Ferrante RJ, Hayden MR, Friedlander RM. Depletion of wild-type huntingtin in mouse models of neurologic diseases. Journal of Neurochemistry. 87: 101-6. PMID 12969257 DOI: 10.1046/J.1471-4159.2003.01980.X  1
2003 Hoogendijk CF, Scholtz CL, Pimstone SM, Ehrenborg E, Kastelein JJ, Defesche JC, Thiart R, du Plessis L, de Villiers JN, Zaahl MG, Delport R, Rubinsztein DC, Raffel LJ, Grim CE, Mediene-Benchekor S, ... ... Hayden MR, et al. Allelic variation in the promoter region of the LDL receptor gene: analysis of an African-specific variant in the FP2 cis-acting regulatory element. Molecular and Cellular Probes. 17: 175-81. PMID 12944120 DOI: 10.1016/S0890-8508(03)00050-1  1
2003 Camp TM, Tyagi SC, Senior RM, Hayden MR. Gelatinase B(MMP-9) an apoptotic factor in diabetic transgenic mice Diabetologia. 46: 1438-1445. PMID 12928773 DOI: 10.1007/s00125-003-1200-y  1
2003 Camp TM, Smiley LM, Hayden MR, Tyagi SC. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats Journal of Hypertension. 21: 1719-1727. PMID 12923405 DOI: 10.1097/00004872-200309000-00022  1
2003 Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dodé C, Morrison PJ, Suchowersky O, Ross CA, Margolis RL, Rosenblatt A, Gómez-Tortosa E, Cabrero DM, Novelletto A, Frontali M, et al. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. American Journal of Human Genetics. 73: 682-7. PMID 12900792 DOI: 10.1086/378133  1
2003 Hayden MR, Tyagi SC. Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure Medical Science Monitor. 9. PMID 12883468  1
2003 Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics. 35: 76-83. PMID 12881722 DOI: 10.1038/Ng1219  1
2003 Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 39: 227-39. PMID 12873381 DOI: 10.1016/S0896-6273(03)00366-0  1
2003 Hayden MR. Predictive testing for Huntington's disease: A universal model? Lancet Neurology. 2: 141-142. PMID 12849232 DOI: 10.1016/S1474-4422(03)00317-X  1
2003 Metzler M, Li B, Gan L, Georgiou J, Gutekunst CA, Wang Y, Torre E, Devon RS, Oh R, Legendre-Guillemin V, Rich M, Alvarez C, Gertsenstein M, McPherson PS, Nagy A, ... ... Hayden MR, et al. Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking. The Embo Journal. 22: 3254-66. PMID 12839988 DOI: 10.1093/Emboj/Cdg334  1
2003 Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Molecular Genetics. 12: 1555-67. PMID 12812983 DOI: 10.1093/Hmg/Ddg169  1
2003 Creighton S, Almqvist EW, MacGregor D, Fernandez B, Hogg H, Beis J, Welch JP, Riddell C, Lokkesmoe R, Khalifa M, MacKenzie J, Sajoo A, Farrell S, Robert F, Shugar A, ... ... Hayden MR, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clinical Genetics. 63: 462-75. PMID 12786753 DOI: 10.1034/J.1399-0004.2003.00093.X  1
2003 Djoussé L, Knowlton B, Hayden M, Almqvist EW, Brinkman R, Ross C, Margolis R, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. American Journal of Medical Genetics. Part A. 119: 279-82. PMID 12784292 DOI: 10.1002/Ajmg.A.20190  1
2003 Hussain NK, Yamabhai M, Bhakar AL, Metzler M, Ferguson SS, Hayden MR, McPherson PS, Kay BK. A role for epsin N-terminal homology/AP180 N-terminal homology (ENTH/ANTH) domains in tubulin binding. The Journal of Biological Chemistry. 278: 28823-30. PMID 12750376 DOI: 10.1074/Jbc.M300995200  1
2003 Wellington CL, Brunham LR, Zhou S, Singaraja RR, Visscher H, Gelfer A, Ross C, James E, Liu G, Huber MT, Yang YZ, Parks RJ, Groen A, Fruchart-Najib J, Hayden MR. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. Journal of Lipid Research. 44: 1470-80. PMID 12730295 DOI: 10.1194/Jlr.M300110-Jlr200  1
2003 Shastry S, Hayden MR, Lucchesi PA, Tyagi SC. Matrix metalloproteinase in left ventricular remodeling and heart failure. Current Cardiology Reports. 5: 200-4. PMID 12691636  1
2003 Hayden MR. New use for folic acid Missouri Medicine. 100: 14-15. PMID 12664703  1
2003 Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, Kayson E, Orme C, Shoulson I. Predictors of nursing home placement in Huntington disease. Neurology. 60: 998-1001. PMID 12654967 DOI: 10.1212/01.Wnl.0000052992.58107.67  1
2003 Tyagi SC, Hayden MR. Role of nitric oxide in matrix remodeling in diabetes and heart failure Heart Failure Reviews. 8: 23-28. PMID 12652156 DOI: 10.1023/A:1022138803293  1
2003 Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain : a Journal of Neurology. 126: 946-55. PMID 12615650 DOI: 10.1093/Brain/Awg077  1
Show low-probability matches.